

Health systems strengthening to arrest the global disability burden: empirical development of prioritised components for a global strategy for improving musculoskeletal health

Andrew M Briggs ¹, Carmen Huckel Schneider ², Helen Slater ¹, Joanne E Jordan ³, Sarika Parambath ², James J Young ^{4,5}, Saurab Sharma ⁶, Deborah Kopansky-Giles ^{4,7}, Swatee Mishrra ⁸, Kristina E Akesson ^{9,10}, Nuzhat Ali ¹¹, Joletta Belton ¹², Neil Betteridge ¹³, Fiona M Blyth ², Richard Brown ¹⁴, Demelash Debere ¹⁵, Karsten E Dreinhöfer ^{16,17,18}, Laura Finucane ^{19,20}, Helen E Foster ²¹, Francesca Gimigliano ²², Scott Haldeman ^{23,24,25,26}, Syed A Haq ²⁷, Ben Horgan ²⁸, Anil Jain ²⁹, Manjul Joshipura ³⁰, Asgar A Kalla ³¹, Jakob Lothe ³², Shuichi Matsuda ³³, Ali Mobasher ^{34,35,36,37}, Lillian Mwaniki ³⁸, Margareta C Nordin ^{39,40}, Marilyn Pattison ^{41,42}, Felipe J J Reis ^{43,44,45}, Enrique R Soriano ^{46,47}, Heather Tick ^{48,49}, James Waddell ⁵⁰, Dieter Wiek ⁵¹, Anthony D Woolf ⁵², Lyn March ^{8,53}

To cite: Briggs AM, Huckel Schneider C, Slater H, *et al.* Health systems strengthening to arrest the global disability burden: empirical development of prioritised components for a global strategy for improving musculoskeletal health. *BMJ Global Health* 2021;**6**:e006045. doi:10.1136/bmjgh-2021-006045

Handling editor Seye Abimbola

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/bmjgh-2021-006045>).

Received 19 April 2021
Accepted 12 May 2021



© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to
Professor Andrew M Briggs;
a.briggs@curtin.edu.au

ABSTRACT

Introduction Despite the profound burden of disease, a strategic global response to optimise musculoskeletal (MSK) health and guide national-level health systems strengthening priorities remains absent. Auspiced by the Global Alliance for Musculoskeletal Health (G-MUSC), we aimed to empirically derive requisite priorities and components of a strategic response to guide global and national-level action on MSK health.

Methods Design: mixed-methods, three-phase design. Phase 1: qualitative study with international key informants (KIs), including patient representatives and people with lived experience. KIs characterised the contemporary landscape for MSK health and priorities for a global strategic response. Phase 2: scoping review of national health policies to identify contemporary MSK policy trends and foci. Phase 3: informed by phases 1–2, was a global eDelphi where multisectoral panellists rated and iterated a framework of priorities and detailed components/actions.

Results Phase 1: 31 KIs representing 25 organisations were sampled from 20 countries (40% low and middle income (LMIC)). Inductively derived themes were used to construct a logic model to underpin latter phases, consisting of five guiding principles, eight strategic priority areas and seven accelerators for action.

Key questions

What is already known?

- Musculoskeletal (MSK) conditions are the most significant contributors to the global burden of disability.
- Despite the burden of disease and multiple ‘calls for action’, global-level guidance for countries and a global strategic response to improve MSK health are lacking.

Phase 2: of the 165 documents identified, 41 (24.8%) from 22 countries (88% high-income countries) and 2 regions met the inclusion criteria. Eight overarching policy themes, supported by 47 subthemes, were derived, aligning closely with the logic model.

Phase 3: 674 panellists from 72 countries (46% LMICs) participated in round 1 and 439 (65%) in round 2 of the eDelphi. Fifty-nine components were retained with 10 (17%) identified as essential for health systems. 97.6% and 94.8% agreed or strongly agreed the framework was valuable and credible, respectively, for health systems strengthening.

Conclusion An empirically derived framework, co-designed and strongly supported by multisectoral stakeholders, can now be used as a blueprint for global and country-level responses to improve MSK health and prioritise system strengthening initiatives.

Key questions

What are the new findings?

- ▶ A global strategic response to improve MSK health and provide guidance to countries is strongly supported by multisectoral stakeholders.
- ▶ National-level policy guidance is nascent, substantiating the need for global-level guidance in health systems strengthening.
- ▶ Priority areas for action align with intuitive foci of the WHO Health System Building Blocks and a framework of eight priority areas (pillars) supported by 59 components are presented and validated.

What do the new findings imply?

- ▶ The proposed framework can now be used as a blueprint by global agencies, such as the WHO and others, to guide countries in formulating responses to address the burden of MSK health impairment.
- ▶ Given the scope for development of national health policy on MSK health, the framework is timely and strongly supported.
- ▶ Individual countries can adapt the framework to suit local contexts; this may be particularly useful for low-income settings where systems strengthening responses for MSK health are less developed and less prioritised.

INTRODUCTION

Musculoskeletal (MSK) health is essential for human function and quality of life. As a group of non-communicable diseases (NCDs) and common sequelae of injury and trauma, MSK conditions and persistent MSK pain account for the largest share of the global disability burden and largest group of conditions requiring rehabilitation across the lifecourse.^{1 2} In 2019, MSK conditions comprised 17% of global years lived with disability (YLDs), and this estimate excludes YLDs associated with MSK injury and trauma and other conditions associated with persistent pain manifesting in MSK tissues and structures.³ MSK conditions also account for significant healthcare expenditure (within the top five conditions by International Classification of Diseases classification), based on available data from member states of the Organisation for Economic Co-operation and Development (OECD),⁴⁻⁶ however proportionate expenditure in low/middle-income countries (LMICs) remains uncertain. The prevalence and impact of MSK conditions, pain and trauma will continue to rise, on a background of rapid population ageing, increasing prevalence of other NCDs and their modifiable risk factors, and increasing rates of injury from minimal trauma fractures associated with bone fragility, falls and road traffic trauma. These circumstances are particularly relevant to LMICs, where the greatest need for care and rehabilitation exists; where the sharpest rise in the number of MSK-attributed YLDs is observed; and where significant disparities exist in awareness, priorities and access to MSK care.^{1 2 7}

Despite unequivocal evidence of the disability burden related to MSK conditions and persistent pain of MSK aetiology,^{3 8 9} substantial healthcare costs^{5 10} and a propensity for delivery of low-value care in many health systems (eg, for back pain^{11 12} and other persistent pain conditions^{13 14}), targeted health systems strengthening

responses are lacking nationally, regionally and globally.^{7 13 15-18} While increased attention is warranted for those NCDs accounting for premature death (cancer, cardiovascular disease, lung disease, diabetes),¹⁹ in parallel there is a strong rationale for more explicit integration of MSK conditions within a broader NCD agenda.^{20 21} This is evidenced by: i) their relevance across the lifecourse (childhood to older age);²² ii) common shared risk factors and effective interventions; iii) increased risk of developing NCDs with a prevalent MSK condition;²³ iv) frequent prevalence of pain and MSK conditions in NCD co- and multi-morbidity presentations;²⁴ and v) chronic disability and work loss.²⁵ Serial Global Burden of Disease (GBD) studies have identified the need for health systems to respond to the burden of MSK conditions, supported by calls in many other publications that MSK conditions should be assigned a greater level of priority in national and global health systems strengthening efforts.^{16 26} This is further exemplified by 2000–2010 Bone and Joint Decade,²⁷ the *Lancet Series* on low back pain²⁸, the *Lancet Series* on chronic pain,²⁹ and planned *Lancet Commission* on osteoarthritis.³⁰

The *Lancet Global Health Commission* argued that formulation of national policy to prioritise prevention and management of NCDs is essential for health systems strengthening.³¹ In particular, global-level leadership is needed to guide countries in formulating and implementing appropriate system-level responses.³² MSK health and pain are explicitly considered in integrated NCD health policies for some, but not all, of OECD member states,²⁰ in the WHO Europe NCD Action Plan³³ and within WHO health system reform initiatives to support healthy ageing³⁴ and rehabilitation in health systems.³⁵ However, system reform attention in LMICs for MSK health and explicit systems strengthening guidance from the WHO for action by member states remains scant. While health policy priorities for integrated management of NCDs are understood,²⁰ the priorities and directions of MSK-specific health policy remain unclear.

The aim of this research is to respond to the health systems strengthening - burden gap for MSK conditions, persistent MSK pain and MSK trauma by empirically deriving prioritised components for a global strategy for improving MSK health. The intentional outcome of this work is to provide a blueprint for a global strategy to support health systems strengthening for MSK health.

METHODS

Design

A three-phase, mixed-methods design was adopted, undertaken from May 2020 to February 2021, auspiced by the Global Alliance for Musculoskeletal Health (G-MUSC). The intention of the three-phase design was to enable diverse data to be collected from phases 1 and 2, which could triangulate to inform phase 3. These discrete phases are described below.

The manuscript is reported in alignment with the GRIPP2-sf and CREDES checklists (online supplemental files 1 and 2).^{36 37} For the purpose of this report, 'MSK health' includes MSK conditions, MSK pain, and MSK injury and trauma.

Patient and public involvement

The design and conduct of the research were overseen by an External Steering Group with explicit patient representation and input. The research intentionally involved patients and members of the public as participants. Patient advocates and advocacy organisations were purposively sampled to ensure that their views and perspectives were explicitly included.

Phase 1: qualitative study

Design

In-depth cross-sectional qualitative study of international key informants (KIs) across multiple health sectors and economies to understand the issues and strategic priorities around improving population-level MSK health, including describing key components of a global strategy.

Sampling and recruitment

Purposive sampling of KIs was undertaken across six cross-sectoral domains (online aggregated supplemental file), intentionally sampling representatives/affiliates of global or international peak organisations in healthcare and health systems strengthening, including patient advocacy organisations. A maximum heterogeneity approach was used across clinical disciplines, genders, geographical regions and economies. Sampling and recruitment have been reported in detail previously.³⁸ Briefly, KIs were identified as leaders of regional or global peak clinical and civil society organisations; representatives of WHO and national Ministries of Health; thought leaders in health systems strengthening and individuals with lived experience holding patient advocacy roles.

Data collection

Audio-recorded semi-structured interviews were conducted in English with each KI by one of three researchers (AMB, HS, JEJ). A semi-structured interview schedule (online aggregated supplemental file) was iteratively developed and piloted to explore KIs' perceptions relating to:

1. The current state of MSK health globally.
2. Actions needed at a global level to address MSK prevention and management to strengthen health systems.
3. The potential value of a global strategy to improve prevention and management of MSK health.
4. Requisite components for a global strategy, including goals of such a strategy.
5. Priorities and opportunities for improving prevention and management of MSK health aligned with the six objectives from the WHO Global Action Plan for Prevention and Control of NCDs (2013–2020).³⁹

Data analysis

Verbatim transcripts were analysed inductively, applying a grounded theory approach by AMB and JEJ, using open, axial and selective coding to derive themes and subthemes across categories. Through selective coding, five categories of data were defined, from which a data-driven logic model was constructed. Categories included:

1. *Context*: a contemporary contextual factor associated with MSK health at the global level.
2. *Goals*: suggested goals or targets for a global strategy on MSK health.
3. *Guiding principles*: concepts or approaches that should underpin all activities or actions within a strategy.
4. *Accelerators*: processes or supports that enable action on strategic priority areas.
5. *Strategic priority areas or 'pillars'*: components or groups of actions considered important for a contemporary global strategy on MSK health.

In this paper, we focus on the strategic priority areas/pillars (category 5), whereas evidence for the other components of the logic model has been reported previously.³⁸ Within each pillar, a number of themes and sub-themes were inductively derived directly from the qualitative data. From these findings, we translated the themes and sub-themes into action-oriented components to build an empirical framework for the latter eDelphi phase (phase 3), consistent with a previously used approach.⁴⁰

Phase 2: policy scoping review

Design

Scoping review of national health policies and strategies relevant to MSK health, based on the methodologic framework proposed by Arksey and O'Malley⁴¹ and adapted by Anderson *et al*⁴² for policy mapping. The review aimed to develop a snapshot of contemporary MSK-specific national policy approaches and priorities. The purpose was to enable policy learning from local policy action and to further inform the framework of components and actions for the eDelphi (phase 3).

Data collection

We defined an MSK policy document as:

1. Government issued; published by government departments or explicitly endorsed by government departments as representing the policy of a specified jurisdiction.
2. Targeting population-level improvement in MSK health; or containing substantial content dedicated to MSK health or any category of MSK health condition (eg, MSK pain, injury, MSK conditions).
3. Containing jurisdiction-wide strategies, action plans or system-level Models of Care or Models of Service Delivery,⁴³ consistent with an earlier approach.²⁰

We searched for policy documents using:

1. A systematic online desktop search across the 30 most populated nations.

2. Identifying policy documents known to the G-MUSC International Coordinating Council members and known policy researchers (expert round), including access to raw data from an earlier integrated NCD policy review of OECD member states.²⁰
3. Snowballing methods that also allowed for inclusion of multinational policies (online aggregated supplemental file).

We also supplemented the pool of documents after the first round of the eDelphi, where respondents were asked to suggest further national policy documents from their country of residence or birth for inclusion (see phase 3 methods). A subset of documents was reviewed by CHS against a priori inclusion criteria. These inclusion criteria were refined further after this initial document review (online aggregated supplemental file). Subsequently, CHS reviewed all policy documents in the yield against the refined inclusion criteria, with further independent verification by AMB and JJY where uncertainties about eligibility or classification were identified. SP then independently confirmed the eligibility of the final set of documents selected for inclusion in the scoping review.

Data analysis and synthesis

Text data were extracted from the policy documents and analysed inductively using content analysis to derive themes and subthemes,⁴⁴ consistent with the principles of a policy scoping review and established methods.^{20 42} In this paper, we present the purpose and formats of the included policies, the MSK conditions included and the policy themes identified. A detailed analysis of themes and subthemes will be reported elsewhere.

Triangulation of data from phases 1 and 2

Data from phases 1 and 2 were triangulated to form an integrated framework of pillars and components in preparation for the phase 3 eDelphi study. As outlined above, data from phase 1 were used to derive the logic model of pillars and detailed components. These components were translated into action-oriented statements. The framework of policy-relevant themes and subthemes derived from the phase 2 policy scoping review was then considered alongside the framework of pillars and actions derived from phase 1 to identify areas of concordance, discordance and gaps. Through a series of meetings, the project team integrated the data from phase 2 into the framework derived from phase 1 to triangulate the datasets. This integrated framework was used as the foundation for the phase 3 eDelphi study.

Phase 3: global eDelphi

Design

A two-round eDelphi was undertaken between October 2020 and January 2021, using Qualtrics (Provo, Utah, USA) software. The eDelphi aimed to present the triangulated findings from phase 1 and phase 2 to a larger global sample.

Sampling and recruitment

Using convenience and purposive methods that aimed to maximise international reach, eDelphi participants were sampled as individuals and organisations across nine multisectoral sampling categories (online aggregated supplemental file). A multipronged sampling frame was developed to include: existing contact databases held by G-MUSC (compliant with privacy standards); a systematic desktop search of clinical and civil society organisations relevant to MSK health and disability across the 30 most populated nations based on United Nations (UN) World Population Prospects (online aggregated supplemental file); and through open invitations on social media platforms. Recruitment was facilitated independent to the research team by the G-MUSC home office (Sydney, Australia).

Data collection

In round 1, the eDelphi survey comprised demographic variables, items reflecting requisite components of a global strategy for MSK health derived from phases 1 and 2 (Numerical Rating Scale of importance (1–9) and a ‘do not know’ option); an item for free-text comments; a free-text item allowing for identification of MSK national policy in the respondent’s country of residence or birth, and an overall rating of support for the draft framework of components (Likert scale 1 (strongly object) to 5 (strongly support)). In round 2, respondents re-rated any components that did not meet the threshold for retention in round 2, identified which components were ‘essential’ (3-point Nominal Response Scale: essential, desirable, unsure), and rated the overall framework for value and credibility (Likert scale 1 (strongly disagree) to 5 (strongly agree)). Since each survey item was written in a brief format, each round was supported by a detailed guidebook, providing explanatory notes. online aggregated supplemental file contain the survey tools and the round 2 guidebook. The guidebook contained detailed information about the scope of each component.

Data analysis

Demographic data were analysed descriptively. Quantitative responses were analysed using the RAND-UCLA method.⁴⁵ Across the items in round 1, the panel median was categorised as 1–3: ‘not important’, 4–6: ‘equivocal’ or 7–9: ‘important’. An item was defined as ‘important’ and retained for round 2 where the overall panel median score was ≥ 7 with level of agreement of $\geq 70\%$ by panellists within the band 7–9. An item with a panel median of 4–6 or other median band with a consensus of $< 70\%$ within that band was defined as ‘uncertain’ and flagged for rerating in round 2. An item with a panel median of 1–3 and a level of agreement of $\geq 70\%$ by panellists within the band 1–3 was defined as ‘unimportant’ and removed from the framework. Free-text comments were analysed using a summative content analysis method. Codes were inductively derived to describe

the content of free-text comments and then counted to provide an indication of relative prominence of the code, consistent with established methods.^{46 47} In round 2, any items requiring re-scoring were analysed in the same way. Frequencies were used to analyse selections for essential items and overall ratings for the framework. An item was considered 'essential' where $\geq 80\%$ of the panel ranked it as essential, consistent with established thresholds.^{40 48}

RESULTS

Qualitative study (phase 1)

Thirty-one KIs (45% women) from 20 countries (40% LMICs) with a mean (SD) of 30.4 (11.2) years of experience in healthcare participated in phase 1. Collectively, the KIs represented 25 peak organisations, including global and regional organisations (online aggregated supplemental file). Across the KIs, 4 (13%) were patient representatives of international or global organisations, while 7 (23%) had a lived experience of an MSK health condition/persistent MSK pain for at least 5 years and 22 (71%) were registered clinicians.

The qualitative data defined the logic model (figure 1) for a global strategy for MSK health, organised as a framework of eight pillars/priority areas, underpinned by detailed components/actions. The pillars and their components/actions were supported by five guiding principles and seven accelerators, described previously.³⁸ Each component was data driven with detailed commentaries and supporting quotes for each component outlined in online aggregated supplemental file.

Policy scoping review (phase 2)

One hundred sixty-five policy documents were identified with 41 (24.8%)^{49–89} retained after exclusions and removal of duplicates, representing 22 countries (20 (90.9%) high-income nations; 2 (9.1%) upper middle-income nations) including: Australia,^{50–52} Belgium,⁵³ Canada,^{49 66 85} Chile,⁶³ Columbia,⁷¹ Denmark,⁷² Finland,⁶² France,^{69 70} Hungary,⁶⁴ Italy,⁵⁸ Ireland,⁸¹ New Zealand,^{73 74 76} Norway,^{59 77} Portugal,⁵⁷ Republic of Korea,⁶⁸ Spain,⁵⁵ Switzerland,^{83 84} Turkey,⁷⁹ UK (England),^{56 80 86} UK (Scotland),^{82 87} UK (Wales),⁸⁹ and USA^{65 67 75 78 88}; and two multi-national regions (European Union,^{60 61} international⁵⁴) (online aggregated supplemental file). We did not identify any eligible documents from LMICs, however, a number of MSK-relevant documents from LMICs were identified from the search (online aggregated supplemental file). Of the 124 excluded documents, most were classified as clinical guidelines (n=56; 45.2%), government reports on burden of disease (n=14; 11.3%), non-government calls to action (n=13; 10.5%) and other non-policy literature (n=14; 11.3%).

A wide variety of documents, purposes and formats was identified, ranging from extensive reviews of the current

health system, MSK services and disease burden, to stand-alone tables of goals and roles and responsibilities. Nine of the included documents had a primary focus MSK health in a broad sense,^{54 56 61 76 79 80 84 86 87} but of these only three were specifically designed as national system-wide policies for MSK health.^{56 79 84} Of the remaining 32 documents, 12 had a primary focus on pain,^{50 53 55 57 62 65–67 69 82 85 89} 6 had a primary focus on occupational health,^{59 60 70 71 75 88} 3 had a primary focus on osteoarthritis,^{49 52 78} 3 had a primary focus on low back pain,^{72–74} 1 had a primary focus on rheumatic inflammatory conditions,⁸¹ and 1 had a primary focus on osteoporosis and fragility fractures.⁵² A further six documents addressed broader health policy as a primary focus (eg, NCDs or a national health plan) and contained a substantial component on general MSK health.^{58 63 64 68 77 83}


We inductively identified eight policy themes, supported by 47 sub-themes (online aggregated supplemental file). Close alignment was observed between these inductively derived policy themes/sub-themes and the empirically derived pillars of the logic model derived in phase 1, providing concurrent validation of the logic model. The 'data and information systems' theme was a distinct theme to the policy review. Across the policy documents, the most broadly covered theme was 'service delivery' (nine sub-themes), followed by 'workforce' (eight sub-themes), and 'medicines and technologies' and 'financing' (six sub-themes each). Other themes were described in less breadth, including 'data and information systems' (five sub-themes); 'leadership and governance' (five sub-themes); 'citizens, consumers and communities' (four sub-themes); and 'research and innovation' (four sub-themes).

eDelphi (phase 3)

Figure 2 summarises the recruitment flow for the eDelphi, with 674 valid responses recorded for round 1 and 439 (65%) for round 2. Demographic characteristics of the Delphi panel are summarised in table 1. Most respondents identified as registered clinicians with approximately half concurrently holding academic roles. Across the eDelphi rounds, approximately 20% (15%–26%) of panellists identified as living with an MSK condition, being an officer of a clinical or professional organisation, working in health policy or service design, or being a thought leader. Seventy-two countries were represented in round 1 (46% LMICs) and 66 in round 2 (44% LMICs), representing all UN geographic regions, with most panellists residing in Europe and Central Asia (36%–39% across rounds 1-2) and North America (27%–24% across rounds 1-2) (figure 3). The 109 panellists who identified as providing an organisation-level response in round 1 represented 116 unique organisations (online aggregated supplemental file).

Fifty-nine (98%) framework components/actions presented in round 1 met the threshold for retaining, with no difference observed between participants

CONTEMPORARY CONTEXTUAL FACTORS RELEVANT TO MUSCULOSKELETAL HEALTH GLOBALLY






Figure 2 Sampling and data processing flow chart for phase 3. *Individuals could represent more than one unique organisation.

At the conclusion of round 1, 96.8% of panellists supported or strongly supported the draft framework. In round 2, 97.6% and 94.8% agreed or strongly agreed the framework was valuable and credible, respectively, for health systems strengthening. No differences in ratings were observed in sensitivity analysis for high-income versus LMICs, individuals versus organisations, or clinicians versus non-clinicians.

DISCUSSION

Given the significant global disability burden associated with MSK conditions, MSK pain and MSK injury and trauma, many and sustained international 'calls for action' on MSK health have been made. Calls for action typically focus on 'what' needs to be done, but not necessarily 'how' to do it and often fail to be data-driven and co-designed with a representative global community that includes people with lived experience.³ This research addresses this key gap. Our scoping review identified that few national system-level strategic policies addressing MSK health exist, highlighting the need for global-level guidance in policy formulation, in particular. We present here, for the first time, a strategic framework for national

MSK health policy and service delivery that has been data driven, co-designed with a representative global community including people with lived experience, and adopts a lifecourse perspective (including children and young people). We have empirically derived contemporary, requisite components for a global strategic response to improve population-level prevention and management of MSK health impairments. The eight priority areas (pillars) with specific components/actions defined from the qualitative phase were strikingly similar to the policy scoping outcomes, suggesting construct validity of the logic model. The eDelphi study further validated these findings and provided evidence for strong international and multi-sectoral support for the framework, irrespective of economic setting.

The eight pillars and their components of the logic model reflect the scope of health systems strengthening at a whole-of-system (macro) level and service (meso) level, consistent with system transformation initiatives in healthy ageing, rehabilitation and pain care.^{13 40 90 91} There was close alignment of our derived eight pillars for action and their components with existing models including the WHO Health Systems

Table 1 Demographic characteristics of the eDelphi panel at rounds 1 and 2. Data are presented as mean (95% CI) for continuous data and frequency count (%) for categorical data.

Characteristic	Panel round 1 (n=674)	Panel round 2 (n=439; 65.1%)
Age	48.3 (47.3 to 49.3)	49.7 (48.5 to 50.8)
Gender	male: 351 (52.1); female: 316 (46.9); other: 7 (1.0)	male: 231 (52.6); female: 206 (46.9); other 2 (0.5)
Type of response		
Individual	565 (83.8)	354 (80.6)
Organisation	109 (16.2)	85 (19.4)
Category of responder*		
Person with a lived experience of MSK health condition	149 (22.1)	94 (21.4)
Registered clinician/health worker	517 (76.7)	332 (75.6)
Officer of a clinical/professional organisation	149 (22.1)	115 (26.2)
Health policy, service design/implementation officer	103 (15.3)	74 (16.9)
Advocacy role	126 (18.7)	87 (19.8)
Thought leader†	128 (19.0)	91 (20.7)
Academic or workforce training position	290 (43.0)	199 (45.3)
WHO officer	3 (0.4)	3 (0.7)
National Ministry of Health officer	8 (1.2)	6 (1.4)
Total years healthcare experience	21.1 (20.2 to 22.0)	22.2 (21.1 to 23.3)
Total years lived experience with MSK health condition‡	18.7 (16.4 to 21.0)	20.9 (17.9 to 23.9)
Economic band (World Bank Classifications 2020\$)		
High income: by country; by participant	39 (54.2); 494 (73.3)	37 (56.1); 329 (74.9)
Low and middle-income: by countries; by participant	33 (45.8); 180 (26.7)	29 (43.9); 110 (25.1)
Global geographic regions: n (%) participants		
East Asia and Pacific	114 (16.9)	80 (18.2)
Europe and Central Asia	241 (35.8)	172 (39.2)
Latin America and Caribbean	54 (8.0)	25 (5.7)
Middle East and North Africa	11 (1.6)	5 (1.1)
North America	179 (26.6)	106 (24.1)
Sub-Saharan Africa	33 (4.9)	22 (5.0)
South Asia	42 (6.2)	29 (6.6)
Highest level of education		
Secondary/high school	5 (0.7)	5 (1.1)
Diploma/certificate/apprenticeship	16 (2.4)	6 (1.4)
University bachelor's degree	83 (12.3)	56 (12.8)
University higher degree (Master's)	200 (29.7)	129 (29.4)
University higher degree (PhD)	229 (34.0)	164 (37.4)
University higher degree (other)	141 (20.9)	79 (18.0)
Clinical disciplines		
Complementary medicine practitioner	1 (0.2)	0 (0)
Anaesthetist/anaesthesiologist	17 (3.3)	10 (3.0)
Chiropractor	68 (13.2)	52 (15.7)

Continued

Table 1 Continued

Characteristic	Panel round 1 (n=674)	Panel round 2 (n=439; 65.1%)
Dietitian/nutritionist	1 (0.2)	1 (0.3)
Emergency medicine physician	1 (0.2)	1 (0.3)
Endocrinologist	2 (0.4)	2 (0.6)
Exercise physiologist/scientist	2 (0.4)	2 (0.6)
General physician	1 (0.2)	1 (0.3)
Gerontologist/geriatrician	1 (0.2)	1 (0.3)
Infectious diseases physician	2 (0.4)	1 (0.3)
Kinesiologist	1 (0.2)	0 (0)
Neurologist	3 (0.6)	3 (0.9)
Nurse/nurse practitioner	6 (1.2)	3 (0.9)
Occupational therapist	23 (4.4)	15 (4.5)
Orthopaedic surgeon	41 (7.9)	23 (6.9)
Osteopath	3 (0.6)	3 (0.9)
Other manual therapist	4 (0.8)	2 (0.6)
Paediatrician	5 (1.0)	4 (1.2)
Physician assistant	1 (0.2)	1 (0.3)
Physiotherapist/physical therapist	222 (42.9)	127 (38.3)
Podiatrist/chiropracist	3 (0.6)	2 (0.6)
Primary care/family physician	4 (0.8)	1 (0.3)
Psychologist/clinical psychologist	2 (0.4)	2 (0.6)
Public health physician	2 (0.4)	1 (0.3)
Rehabilitation and physical medicine physician	42 (8.1)	29 (8.7)
Rheumatologist (including paediatric rheumatologist)	60 (11.6)	45 (13.6)

*Categories are not mutually exclusive; hence proportions exceed 100%.

†Defined as having published at least two peer-reviewed papers or health policies in the last 5 years related to global health systems or health services reform for MSK health, MSK pain, injury, non-communicable disease, ageing, disability or rehabilitation.

‡Answered only by panellists who identified as living with an MSK health condition for at least 5 years.

§World Bank Classifications: <https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups>.

MSK, musculoskeletal; WHO, World Health Organization.

Building Blocks model⁹² and a contemporary framework of value-creating learning health systems.⁹³ Together with findings from the policy review, this provides confidence in the construct validity of our proposed logic model and should facilitate interpretation and adoption by policymakers and other stakeholders.

The most prominent pillars, evidenced by the strength of qualitative data, were ‘engaging, empowering and educating’ (pillar 1); ‘leadership, governance and shared accountability’ (pillar 2); ‘service delivery’ (pillar 4); and ‘research and innovation (pillar 8)’. Cross-cutting themes across these areas were the importance of a lifecourse approach (including children), targeting improvement in function and quality of life, and reducing health inequity, as articulated in the five guiding principles of the logic model. Importantly, these data-driven guiding principles also align with other global initiatives, for

example, the WHO Rehabilitation 2030 Agenda;⁹⁴ WHO Framework on integrated, people-centred health services;³² WHO Global Strategy on Human Resources for Health: Workforce 2030;⁹⁵ WHO Model of Healthy Ageing;⁹⁶ and the UN Decade of Healthy Ageing 2020–2030.⁹¹ Harmonisation of principles with these extant frameworks will be important for adoption and facilitating implementation activity.

Cross-sectoral partnerships (pillar 1); global and national leadership on MSK health prioritisation and extending health indicators to consider function (pillar 2); and early diagnosis, triage and prioritising high-value care (pillar 4) were considered essential components by the eDelphi panel. While there were less granular data on financing models (pillar 3) and access to essential medicines and technologies (pillar 5), panellists still identified essential components within these pillars. Although building population health surveillance capacity




Figure 3 Global geographic heatmap of participants in phase 3, powered by Microsoft Excel (Microsoft Corporation, Redmond, Washington, USA). The continent of Antarctica is excluded from the image. (A) Illustrates the distribution of countries represented in phase 3 (n=72). Consistent blue shading reflects the countries represented. (B) Illustrates the distribution of participants (n=674) by country, ranging from 1 to 138 participants by country, represented by graded shading where darker shading indicates a greater number of participants in a given country.

(pillar 7) was considered important, it did not meet the threshold for an essential component (scored by 77% of the panel, rather than the threshold of 80%). This observation resonates with recent findings of limited inclusion of MSK conditions in population health surveys.⁹⁷ We infer this may be due to the strong representation of clinician panellists placing more emphasis on community engagement and service delivery components, compared with system-level actions like population health surveillance. Panellists from LMICs identified more components as ‘essential’ compared with panellists from high-income settings. Specifically, leadership from the WHO; establishment of essential packages of care; inclusion of MSK health in primary and secondary prevention initiatives for NCDs; access to low-cost technologies and interventions; building capacity in the primary care workforce and educating health practitioners were considered essential by panellists in LMICs, which likely reflects key priorities in these settings. These setting-specific differences in

priorities underline the importance of providing global-level guidance that is adaptable to local context; a point strongly enforced by KIs, ‘*You can’t take a strategy from one country and just implement it in another country*’ (ID4, France) and also a guiding principle in the logic model. While strongly supported, no components in the ‘research and innovation’ pillar were considered ‘essential’, suggesting that the panel prioritised health systems strengthening in other areas at this time. Similarly, the panel rating of importance for item 1.1d, relating to the built environment, was below the threshold for inclusion. This suggests the panel placed more importance on direct health system strengthening efforts, despite KIs’ perceptions in phase 1, recent evidence,⁹⁸ and a programme of work in WHO positioning the importance of the built environment for optimising functional ability in people with MSK health conditions and older people (eg, WHO Global Network for Age-friendly Cities and Communities). The box below highlights the essential actions required at a global



Table 2 Summary of quantitative outcomes from eDelphi rounds 1 and 2. The component descriptions reflect the revisions applied after free-text data analysis from Round 1 and additions from the Phase 2 policy scoping review. Bolded scores reflect those components identified as essential by at least 80% of the panel.

Component	Pooled panel				High-income countries panel				Low/middle-income countries panel						
	Round 1		Round 2		Round 1		Round 2		Round 1		Round 2				
	Median in 1-9 NRS (IQR)	n (%) in median band 7-9	N (%) ranked essential	N	Median in 1-9 NRS (IQR)	n (%) in median band 7-9	N (%) ranked essential	N	Median in 1-9 NRS (IQR)	n (%) in median band 7-9	N (%) ranked essential	N			
Pillar 1: engaging, empowering and educating citizens, communities, organisations and governments to act on MSK health															
1.1a: improving prevention and management of MSK health requires engagement and partnerships with citizens, patients and civil society organisations.	9 (1)	610 (90.6)	674	391 (90.1)*	434	9 (1)	444 (89.9)	494	293 (90.4)*	324	9 (1)	166 (92.2)	180	98 (89.1)*	110
1.1b: improving prevention and management of MSK health requires engagement and partnerships with industry, workplaces and employers.	8 (2)	582 (86.4)	674	351 (80.9)*	434	8 (2)	427 (86.4)	494	264 (81.5)*	324	8 (2)	155 (86.1)	180	87 (79.1)	110
1.1c: improving prevention and management of MSK health requires engagement and partnerships with third-party payers/insurers.	7 (2)	522 (77.4)	674	281 (64.7)	434	8 (2)	393 (79.6)	494	212 (65.4)	324	8 (3)	129 (71.7)	180	69 (62.7)	110
1.1d: improving prevention and management of MSK health requires engagement and partnerships with the built environment sector.	8 (2)	421 (62.5)	674	n/r	n/r	7 (2)	295 (59.7)	494	n/r	n/r	8 (3)	126 (70.0)	180	n/r	n/r
1.1e: improving prevention and management of MSK health requires engagement and partnerships with schools and education facilities.	9 (1)	545 (80.9)	674	308 (71.0)	434	8 (2)	394 (79.8)	494	222 (68.5)	324	8 (2)	151 (83.9)	180	86 (78.2)	110
1.1f: improving prevention and management of MSK health requires engagement and partnerships with national and subnational governments.	9 (1)	592 (87.8)	674	363 (83.6)*	434	9 (1)	432 (87.4)	494	274 (84.6)*	324	9 (1)	160 (88.9)	180	89 (80.9)*	110
1.2: improving prevention and management of MSK health requires education across the following sectors: schools and higher education facilities; workplaces; health professionals and the community.	9 (1)	643 (96.4)	667	398 (91.7)*	434	9 (1)	471 (96.1)	490	293 (90.4)*	324	9 (1)	172 (97.2)	177	105 (95.5)*	110
1.3: improving prevention and management of MSK health requires globally relevant educational messages contextualised to local settings.	9 (1)	624 (93.6)	667	310 (71.4)	434	9 (1)	458 (93.5)	490	228 (70.4)	324	9 (1)	166 (93.8)	177	82 (74.5)	110
1.4: Use mechanisms to drive public education, including empowering people with lived experience to share stories and co-design messages; mass and social media; peer support models and engaging civil society and professional organisations.	8 (1)	606 (91.7)	661	279 (64.3)	434	8 (2)	446 (91.8)	486	213 (65.7)	324	9 (1)	160 (91.4)	175	66 (60.0)	110

Continued

Table 2 Continued

Component	Pooled panel				High-income countries panel				Low/middle-income countries panel					
	Round 1		Round 2		Round 1		Round 2		Round 1		Round 2			
	Median in 1–9 NRS (IQR)	n (%) in band 7–9 N	N (%) ranked essential	N	Median in 1–9 NRS (IQR)	n (%) in band 7–9 N	N (%) ranked essential	N	Median in 1–9 NRS (IQR)	n (%) in band 7–9 N	N (%) ranked essential	N		
Pillar 2: leadership, governance and shared accountability														
2.1: MSK health should be explicitly integrated with broader reform efforts for non-communicable diseases (NCDs).	9 (1)	587 (90.9)	297 (68.9)	431	9 (1)	435 (92.2)	472	212 (66.0)	321	8 (1.25)	152 (87.4)	174	85 (77.3)	
2.2: Universal Health Coverage essential care packages and/or insurance schemes should include prevention and management of MSK health impairment.	9 (1)	589 (90.3)	314 (72.9)	431	9 (1)	430 (89.6)	480	232 (72.3)	321	9 (1)	159 (92.4)	172	82 (74.5)	
2.3: strategic global responses for MSK health should explicitly link with and support implementation of existing global and national health systems strengthening efforts.	9 (1)	609 (94.1)	289 (67.1)	431	9 (1)	449 (94.1)	477	212 (66.0)	321	9 (1)	160 (94.1)	170	77 (70.0)	
2.4: global leadership from the WHO in prioritising MSK health is essential to drive a global response to the burden of MSK health impairment.	8 (2)	559 (88.0)	320 (74.2)	431	8 (2)	411 (88.0)	467	232 (72.3)	321	9 (1.75)	148 (88.1)	168	88 (80.0)*	
2.5: country-level leadership is needed to prioritise MSK health impairment by national governments.	9 (1)	610 (95.9)	366 (84.9)*	431	9 (1)	450 (95.7)	470	275 (85.7)*	321	9 (1)	160 (96.4)	166	91 (82.7)*	
2.6: leadership is needed from professional and civil societies and citizens that extends beyond just MSK health.	8 (2)	531 (83.2)	256 (59.4)	431	8 (2)	393 (83.3)	472	186 (57.9)	321	8 (2)	138 (83.1)	166	70 (63.6)	
2.7: global and national multi-sectoral and inter-ministerial leadership is needed to prioritise action on policy and financing for MSK health.	8 (2)	550 (88.9)	264 (61.3)	431	8 (2)	408 (89.9)	454	198 (61.7)	321	8 (2)	142 (86.1)	165	66 (60.0)	
2.8: global and national health and performance indicators must extend beyond mortality reduction to consider function and participation.	9 (1)	610 (96.2)	368 (85.4)*	431	9 (1)	452 (96.6)	468	274 (85.4)*	321	9 (1)	158 (95.2)	166	94 (85.5)*	
2.9: a meaningful, acceptable and internationally comparable classification system is needed for MSK health.	8 (2)	557 (89.4)	268 (62.2)	431	8 (2)	401 (87.6)	458	193 (60.1)	321	9 (1)	156 (94.5)	165	75 (68.2)	
2.10: legislation and regulation are needed to sustain reform efforts in health systems strengthening for NCDs, including MSK health.	8 (2)	535 (87.2)	274 (63.6)	431	8 (2)	383 (85.3)	449	199 (62.0)	321	8 (1)	152 (92.1)	165	75 (68.2)	
Pillar 3: financing														
3.1: existing healthcare financing models need to integrate health promotion and healthcare delivery for MSK health.	8 (1)	574 (92.7)	619	344 (80.2)*	429	9 (1)	420 (92.1)	456	253 (79.1)	320	8 (1)	154 (94.5)	163	91 (83.5)*

Continued

Table 2 Continued

Component	Pooled panel				High-income countries panel				Low/middle-income countries panel					
	Round 1		Round 2		Round 1		Round 2		Round 1		Round 2			
	Median 1-9 NRS (IQR)	n (%) in median band 7-9	N ranked essential	N (%) ranked essential	Median 1-9 NRS (IQR)	n (%) in median band 7-9	N ranked essential	N (%) ranked essential	Median 1-9 NRS (IQR)	n (%) in median band 7-9	N ranked essential	N (%) ranked essential		
3.2: financing models for MSK health should accommodate flexibility for public-private partnerships, partnerships with civil society, international aid, tagged donorships and revenue-raising strategies.	8 (2)	480 (76.7)	626	214 (49.9)	429	343 (74.4)	461	146 (45.6)	320	8 (2)	137 (83.0)	165	68 (62.4)	109
3.3: support multinational foreign aid for MSK care in low-resource settings.	8 (2)	474 (75.7)	626	215 (50.1)	429	334 (72.4)	461	143 (44.7)	320	9 (1)	140 (84.8)	165	72 (66.1)	109
3.4: allocated funding, essential medicines funding and donor funding for MSK health and injury care need to be quarantined.	8 (2)	465 (74.6)	623	178 (41.5)	429	323 (70.5)	458	117 (36.6)	320	8 (2)	142 (86.1)	165	61 (56.0)	109
3.5: financing for MSK healthcare should cover well-defined, high-value (effective, safe, affordable) packages of care for prevention, diagnosis and management, particularly for community-based interventions.	8 (1)	554 (89.8)	617	340 (79.3)	429	408 (89.5)	456	262 (81.9)*	320	8 (2)	146 (90.7)	161	78 (71.6)	109
3.6: financing models should incentivise prevention and integrated interdisciplinary care for MSK health conditions.	9 (1)	554 (89.8)	617	318 (74.1)	429	414 (90.8)	456	243 (75.9)	320	8 (2)	140 (87.0)	161	75 (68.8)	109
Pillar 4: service delivery														
4.1: service models for MSK conditions need to support early diagnosis and triage and management through local care pathways.	9 (1)	574 (93.0)	617	354 (82.7)*	428	421 (92.3)	456	261 (81.8)*	319	9 (1)	153 (95.0)	161	93 (85.3)*	109
4.2: local care pathways should support essential packages of affordable, effective and safe care for MSK health impairment, while de-adopting care that is not supported by evidence, is costly and potentially harmful.	9 (1)	564 (91.7)	615	335 (78.3)	428	416 (91.6)	454	247 (77.4)	319	9 (1)	148 (91.9)	161	88 (80.7)*	109
4.3: services for MSK healthcare should be integrated with service models for NCDs and services that target the broader social determinants of health.	8 (2)	541 (88.5)	611	260 (60.7)	428	395 (87.8)	450	188 (58.9)	319	8 (1)	146 (90.7)	161	72 (66.1)	109
4.4: evidence-based diagnostic and therapeutic practices should be prioritised in service models over approaches that are not supported by evidence, are costly and potentially harmful (low-value).	9 (1)	560 (92.1)	608	351 (82.0)*	428	411 (91.9)	447	256 (80.3)*	319	9 (1)	149 (92.6)	161	95 (87.2)*	109

Continued

Table 2 Continued

Component	Pooled panel				High-income countries panel				Low/middle-income countries panel				
	Round 1		Round 2		Round 1		Round 2		Round 1		Round 2		
	Median in 1-9 NRS (IQR)	n (%) in median band 7-9	N ranked essential	N (%) ranked essential	Median in 1-9 NRS (IQR)	n (%) in median band 7-9	N ranked essential	N (%) ranked essential	Median in 1-9 NRS (IQR)	n (%) in median band 7-9	N ranked essential	N (%) ranked essential	
4.5: service models for MSK conditions should support integrated, person-centred care that targets functional ability through a biopsychosocial approach.	9 (1)	574 (94.4)	608	334 (78.0)	428	422 (94.4)	447	249 (78.1)	319	9 (1)	152 (94.4)	161	85 (78.0)
4.6: service models for MSK healthcare should promote community-based interdisciplinary care.	8 (1)	565 (93.2)	606	280 (65.4)	428	416 (93.3)	446	204 (63.9)	319	8 (1)	149 (93.1)	160	76 (69.7)
4.7: MSK care should be integrated into existing community-based or regionally based service models for NCD care.	8 (1)	541 (89.9)	602	248 (57.9)	428	394 (88.7)	444	182 (57.1)	319	9 (1)	147 (93.0)	158	66 (60.6)
4.8: community-led service models for MSK healthcare should be co-designed by the community.	8 (2)	520 (86.5)	601	189 (44.2)	428	379 (85.4)	444	141 (44.2)	319	9 (1.5)	141 (89.8)	157	48 (44.0)
4.9: service models should prioritise access to health information and care to vulnerable groups.	8 (1)	544 (90.5)	601	267 (62.4)	428	399 (89.9)	444	190 (59.6)	319	9 (1)	145 (92.4)	157	77 (70.6)
4.10: primary and secondary prevention initiatives for NCDs should include MSK health.	8 (2)	541 (90.5)	598	330 (77.1)	428	397 (90.0)	441	242 (75.9)	319	8 (2)	144 (91.7)	157	88 (80.7)*
4.11: MSK-specific primary prevention initiatives should be delivered where evidence of clinical and cost-effectiveness exists.	9 (1)	562 (94.0)	598	317 (74.1)	428	415 (94.1)	441	235 (73.7)	319	9 (1)	147 (93.6)	157	82 (75.2)
4.12: national injury (sport, workplace, falls) and trauma prevention strategies and campaigns are needed.	8 (2)	499 (83.4)	598	237 (55.4)	428	359 (81.4)	441	164 (51.4)	319	9 (2)	140 (89.2)	157	73 (67.0)
Pillar 5: equitable access to medicines and technologies													
5.1: countries need to identify, resource and provide access to essential therapeutics for priority MSK conditions.	8 (2)	516 (86.4)	597	345 (80.8)*	427	371 (84.3)	440	256 (80.3)*	319	9 (1)	145 (92.4)	157	89 (82.4)*
5.2: global and national prioritisation and management are needed in innovation of, and access to, low-cost assistive devices, technologies and interventions that support function and participation.	8 (2)	493 (82.6)	597	288 (67.4)	427	353 (80.2)	440	201 (63.0)	319	9 (1)	140 (89.2)	157	87 (80.6)*
Pillar 6: workforce (building workforce capacity, systems and tools)													
6.1: increase the number of medical specialists and allied health practitioners for MSK healthcare in LMICs.	8 (2)	470 (78.9)	596	275 (64.4)	427	337 (76.8)	439	193 (60.5)	319	8 (2)	133 (84.7)	157	82 (75.9)

Continued

Table 2 Continued

Component	Pooled panel				High-income countries panel				Low/middle-income countries panel				
	Round 1		Round 2		Round 1		Round 2		Round 1		Round 2		
	Median in 1-9 NRS (IQR)	n (%) in median band 7-9 N	N (%) ranked essential	N	Median in 1-9 NRS (IQR)	n (%) in median band 7-9 N	N (%) ranked essential	N	Median in 1-9 NRS (IQR)	n (%) in median band 7-9 N	N (%) ranked essential	N	
6.2: build capacity in the local existing community-based workforce to contribute to basic MSK health and injury care.	8 (1)	535 (89.8)	294 (68.9)	427	8 (2)	389 (88.6)	439	206 (64.6)	319	9 (1)	146 (93.0)	157	88 (81.5)*
6.3: establish flexible service models to enable the non-medical workforce (eg, nurses, pharmacists, allied health practitioners) to adopt advanced practice/extended scope roles that improve access to evidence-based triage, assessment and management of MSK conditions and injuries.	9 (1)	538 (90.4)	289 (67.7)	427	9 (1)	396 (90.4)	438	220 (69.0)	319	9 (1)	142 (90.4)	157	69 (63.9)
6.4: integrate MSK health into curricula across medical disciplines and increase the number of MSK medical specialist training positions in LMICs.	8 (2)	503 (84.7)	317 (74.2)	427	8 (2)	360 (82.4)	437	233 (73.0)	319	9 (1)	143 (91.1)	157	84 (77.8)
6.5: build skills-based competencies across medical, nursing and allied health disciplines (and non-clinical roles in LMICs) in the identification of MSK health problems and basic prevention and management practices.	9 (1)	561 (94.4)	317 (74.2)	427	9 (1)	409 (93.6)	437	236 (74.0)	319	9 (1)	152 (96.8)	157	81 (75.0)
6.6: extend training curricula for prelicensure medical, nursing, pharmacy and allied health clinicians in MSK health, persistent pain and injury care within a person-centred, biopsychosocial model.	8 (2)	525 (88.4)	286 (67.0)	427	8 (2)	388 (88.8)	437	213 (66.8)	319	8 (2)	137 (87.3)	157	73 (67.6)
6.7: educate healthcare workers and health planners to deliver information and care aligned to positive health behaviours for MSK health and other NCDs.	8 (1)	544 (91.6)	318 (74.5)	427	8 (1)	398 (91.1)	437	232 (72.7)	319	9 (1)	146 (93.0)	157	86 (79.6)*
6.8: increase remuneration for the health workforce in LMICs to maintain workforce volumes.	8 (2)	465 (78.3)	241 (56.4)	427	8 (2)	326 (74.6)	437	157 (49.2)	319	9 (1)	139 (88.5)	157	84 (77.8)
Pillar 7: surveillance (monitoring population health)													
7.1: build country-level population health surveillance capacity to monitor incidence, prevalence and impact of MSK conditions.	8 (2)	304 (84.8)	282 (66.0)	427	8 (2)	363 (83.1)	437	206 (64.6)	319	8 (2)	141 (89.8)	157	76 (70.4)
7.2: include metrics on function, participation, quality of life and care experience in national health surveillance systems.	8 (2)	531 (89.4)	329 (77.0)	427	8 (2)	386 (88.3)	437	244 (76.5)	319	9 (1)	145 (92.4)	157	85 (78.7)

Continued

Table 2 Continued

Component	Pooled panel			High-income countries panel			Low/middle-income countries panel				
	Round 1	Round 2	Round 2	Round 1	Round 2	Round 2	Round 1	Round 2	Round 2		
	Median in 1-9 NRS (IQR)	n (%) in median band 7-9	N ranked essential	Median in 1-9 NRS (IQR)	n (%) in median band 7-9	N ranked essential	Median in 1-9 NRS (IQR)	n (%) in median band 7-9	N ranked essential		
7.3: surveillance outcomes should be disaggregated by age, sex and gender, geography, socioeconomic status and by the International Classification of Diseases and International Classification of Functioning, Disability and Health systems.	8 (2)	457 (77.1)	593	8 (2)	327 (75.0)	436	8 (2)	130 (82.8)	157	67 (62.0)	108
Pillar 8: research and innovation											
8.1: <i>research priority area 1</i> - epidemiological and population health research: lifecourse risk factors; risk assessment tools; core outcomes for population health research.	8 (2)	513 (86.5)	593	8 (2)	368 (84.4)	436	9 (1)	145 (92.4)	157	84 (77.8)	108
8.2: <i>research priority area 2</i> - public health research; public health interventions to shift health behaviours; impact of MSK health on other conditions; dynamic systems modelling to inform public health policy.	8 (2)	526 (88.7)	593	8 (2)	386 (88.5)	436	9 (2)	140 (89.2)	157	78 (72.2)	108
8.3: <i>research priority area 3</i> - health policy and systems research: implementation of MSK service models across contexts; strategies to reduce health inequalities and access inequities; development of a MSK health classification system; effectiveness and acceptability of digital technologies to support MSK care and surveillance.	8 (2)	519 (87.5)	593	8 (2)	379 (86.9)	436	8 (1.25)	140 (89.2)	157	76 (70.4)	108
8.4: <i>research priority area 4</i> - clinical and basic science research: mechanisms associated with MSK conditions, including persistent pain; curative therapies for MSK conditions; biomarkers, assays and diagnostic applications; and extend evidence for non-surgical and non-pharmacological interventions.	9 (1)	533 (89.9)	593	9 (1)	386 (88.5)	436	9 (1)	147 (93.6)	157	85 (78.7)	108
8.5: <i>research priority area 5</i> - health economics research: cost of MSK health conditions and injuries to communities and governments; cost-effectiveness of treatments; cost-effectiveness of integrating MSK health prevention and management within broader NCD care; and return on MSK health investment for other sectors such as workforce participation.	9 (1)	549 (92.7)	592	9 (1)	404 (92.7)	436	9 (1)	145 (92.9)	156	78 (72.2)	108

Continued

Table 2 Continued

Component	Pooled panel			High-income countries panel			Low/middle-income countries panel					
	Round 1			Round 2			Round 1			Round 2		
	Median in 1–9 NRS (IQR)	n (%) in median band 7–9	N	Median in 1–9 NRS (IQR)	n (%) in median band 7–9	N	Median in 1–9 NRS (IQR)	n (%) in median band 7–9	N	Median in 1–9 NRS (IQR)	n (%) in median band 7–9	N
8.6: <i>research capacity priority 1</i> - support national-level MSK health research; multinational and interdisciplinary research collaborations and lower-resource settings to undertake critical local research.	8 (1)	527 (89.2)	591	8 (1)	385 (88.3)	436	8 (1)	142 (91.6)	155	8 (1)	216 (67.9)	318
8.7: <i>research capacity priority 2</i> - support co-design of research by people with lived experience of various MSK health conditions and clinicians.	8 (2)	502 (84.9)	591	8 (2)	368 (84.4)	436	8 (2)	134 (86.5)	155	8 (2)	177 (55.7)	318
8.8: increase the proportion of research funding allocated to MSK research and allocate additional funding leveraged through public-private partnerships.	8 (1)	523 (88.6)	590	8 (1)	376 (86.4)	435	8 (1)	147 (94.8)	155	8 (1)	194 (61.0)	318
8.9: support innovation sharing between countries and between researchers and clinicians.	8 (2)	524 (89.0)	589	8 (2)	381 (87.8)	434	8 (2)	143 (92.3)	155	8 (2)	205 (64.5)	318
8.10: support research that harnesses the emerging potential of digital technologies and the collection and use of 'big data' and machine learning.	8 (2)	500 (84.9)	589	8 (2)	359 (82.7)	434	8 (2)	141 (91.0)	155	8 (2)	168 (52.8)	318

*Components identified as essential by at least 80% of the panel. IQR, inter-quartile range; LMIC(s), low- and middle-income country(ies); MSK, musculoskeletal; NCD(s), non-communicable disease(s); n/r, not rated; NRS, Numerical Rating Scale; WHO, World Health Organization.

Summary of essential, globally relevant health systems strengthening actions for MSK health

- ▶ Drive engagement and partnerships with: citizens, patients and civil society organisations; industry, workplaces and employers; national and subnational governments.
- ▶ Deliver public education across the following sectors: schools and higher education facilities; workplaces; health professionals; and the community, to improve prevention and management of MSK health.
- ▶ Foster and support country-level leadership to prioritise MSK health impairment by national governments.
- ▶ Extend global and national health and performance indicators beyond mortality reduction to consider function and participation.
- ▶ Integrate health promotion and healthcare delivery for MSK health into existing healthcare financing models.
- ▶ Ensure service models for MSK conditions support early diagnosis and triage and management through local care pathways.
- ▶ Prioritise evidence-based diagnostic and therapeutic practices in service models over approaches that are not supported by evidence, are costly and potentially harmful.
- ▶ Identify, resource and provide access to essential therapeutics for priority MSK conditions.

level to strengthen health systems for prevention and management of MSK health.

The policy scoping review identified a large number of national clinical guidelines and reports of national MSK disease burden, but few system-level policies, strategies or action plans were identified. This suggests that while there has been positive progress in articulating burden of disease and clinical management, system-level strengthening is rarely purposively and strategically developed in current policy. We found only three documents that could be considered system-wide strategy or policy for MSK health conditions at the national level^{56 79 84} and two at the international level^{54 60} and there was very limited policy representation from LMICs. Earlier research identified integration of MSK health into policies for management of NCDs in Member States of the OECD, although the extent of integration varied across countries.²⁰ In the policy documents we reviewed, there was a consistent focus on the MSK burden of disease, for which the evidence is well developed and strong.² Most documents also described broad goals and detailed service delivery and workforce strengthening priorities, with considerably less focus on governance, technologies and information systems. Only a few documents included aspects of monitoring, innovation and community engagement. Collectively, the pool of documents contained a breadth of key issues, themes and principles, although very few existing national policies addressed all the pillars of the logic model and the policy themes we inductively derived. Global health policy development may, therefore, learn from this breadth of many experiences, rather than depth

of a few. The scoping review findings also highlight a dearth of MSK health policy among LMICs, which may reflect less developed systems for MSK health in these settings. This presents an opportunity to positively influence the MSK-attributed burden of disease in these countries by providing guidance for policy evolution in healthy ageing, rehabilitation, NCD prevention and control, and road traffic trauma.

The strength of this work lies in the triangulation of several evidence sources to build and validate a data-driven framework of components for a strategic response to improve MSK health globally. The wide sampling frame, inclusion of organisation-level representation and those with lived experience of MSK health impairment ensured a broad range of perspectives were considered in the co-design of the framework. While proportionally more panellists from high-income settings participated in the eDelphi, almost half the countries represented were LMICs. This represents a significant step forward in including perspectives of stakeholders from LMICs than has been achieved previously. Further, no differences in outcomes were identified between panellists in high-income countries and LMICs, apart from more essential components identified by panellists in LMICs. Nonetheless, we acknowledge limited representation from residents of countries in Africa and the Middle East. It will be important to conduct targeted research in these settings to ensure that the components of the proposed framework are acceptable and feasible to stakeholders in these settings. Here, the role of regional offices of the WHO, for example, may be particularly important in facilitating engagement and further co-design and evolution of the components of the framework, and critically, in planning for any implementation. Further research may also be conducted in local languages to facilitate greater involvement from people in LMICs, as their participation may have been limited because the current study was conducted in English only.⁹⁹ The modality of data collection may also not have been acceptable to people in LMICs. The nature of the policy scoping review precluded a systematic review, yet we applied systematic search processes to identify the policies. Notwithstanding, we may have missed policies from less populated countries that were not systematically desktop searched, or relevant policy content if contained in documents relating to subnational health policy or captured in adjacent policy fields such as education, injury prevention from violence, road safety, sport and health system regulation.

CONCLUSION

This empirically derived framework of strategic priority areas and detailed components/actions, validated by a contemporary policy scoping review and eDelphi, may be used as a blueprint to develop a

global strategy and action plan on MSK health. Individual countries may also use this as a blueprint to initiate or progress national health system strengthening responses for MSK health. This will be particularly important in LMICs where relatively less policy attention to MSK health has been identified.

Author affiliations

¹Curtin School of Allied Health, Faculty of Health Sciences, Curtin University, Perth, Western Australia, Australia

²Menzies Centre for Health Policy and Economics, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia

³HealthSense (Aust) Pty, Ltd, Melbourne, Victoria, Australia

⁴Department of Research, Canadian Memorial Chiropractic College, Toronto, Ontario, Canada

⁵Center for Muscle and Joint Health, Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark

⁶Department of Physiotherapy, Kathmandu University School of Medical Sciences, Dhulikhel, Kavre, Nepal

⁷Department of Family and Community Medicine, University of Toronto Faculty of Medicine, Toronto, Ontario, Canada

⁸Sydney Musculoskeletal, Bone and Joint Health Alliance. Institute of Bone and Joint Research, Kolling Institute, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia

⁹Department of Clinical Sciences Malmö, Clinical and Molecular Osteoporosis Research Unit, Lund University, Malmö, Sweden

¹⁰Department of Orthopedics, Skane University Hospital, Malmö, Sweden

¹¹Health Improvement, Public Health England, London, UK

¹²Global Alliance of Partners for Pain Advocacy, International Association for the Study of Pain, Washington, DC, USA

¹³Neil Betteridge Associates, London, UK

¹⁴World Federation of Chiropractic, Toronto, Ontario, Canada

¹⁵Rehabilitation International (Africa Region), Addis Ababa, Ethiopia

¹⁶Medical Park Berlin Humboldtstraße, Berlin, Germany

¹⁷Center for Musculoskeletal Surgery, Charité Universitätsmedizin, Berlin, Germany

¹⁸Global Alliance for Musculoskeletal Health, Berlin, Germany

¹⁹International Federation of Orthopaedic Manipulative Physical Therapists Incorporated (IFOMPT), World Physiotherapy, London, UK

²⁰Sussex MSK Partnership, Physiotherapy Department, National Health Service, Brighton, UK

²¹Population Health Institute, Newcastle University, Newcastle upon Tyne, UK

²²Department of Mental and Physical Health and Preventive Medicine, University of Campania "Luigi Vanvitelli", Napoli, Italy

²³Department of Neurology, University of California, Irvine, California, USA

²⁴Southern California University of Health Sciences, Whittier, California, USA

²⁵Faculty of Health Sciences, University of Ontario Institute of Technology, Toronto, Ontario, Canada

²⁶World Spine Care, Santa Ana, California, USA

²⁷Rheumatology Department, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

²⁸Consumer and Community Involvement Program, West Australian Health Translation Network, Perth, Western Australia, Australia

²⁹Department of Physical Medicine and Rehabilitation, Santokba Durlabhji Memorial Hospital, Jaipur, India

³⁰AO Alliance Foundation, Davos, Switzerland

³¹Department of Medicine, University of Cape Town, Cape Town, South Africa

³²Norwegian Council for Musculoskeletal Health, Oslo, Norway

³³Department of Orthopaedic Surgery, Kyoto University, Kyoto, Japan

³⁴Research Unit of Medical Imaging, Physics and Technology, Faculty of Medicine, University of Oulu, Oulu, Finland

³⁵Department of Regenerative Medicine, State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania

³⁶Departments of Orthopedics, Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands

³⁷Department of Joint Surgery, First Affiliated Hospital of Sun Yat-sen University Guangzhou, Guangdong, People's Republic of China

³⁸Global Alliance for Musculoskeletal Health, Kenya

³⁹Department of Orthopedic Surgery and Environmental Medicine, NYU Grossman School of Medicine, New York University, New York City, NY, USA

⁴⁰Department of Occupational and Industrial Orthopedic Center, NYU Grossman School of Medicine, New York University, New York City, NY, USA

⁴¹World Federation of Occupational Therapists (WFOT), London, UK

⁴²MPOT/Access Fitness and Talking Matters, Adelaide, South Australia, Australia

⁴³Physical Therapy Department, Instituto Federal do Rio de Janeiro (IFRJ), Rio de Janeiro, Brazil

⁴⁴Clinical Medicine Department, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil

⁴⁵Pain in Motion Research Group, Department of Physiotherapy, Human Physiology and Anatomy, Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel, Brussels, Belgium

⁴⁶Rheumatology Unit, Internal Medicine Services and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

⁴⁷Pan-American League of Associations for Rheumatology, Miami, Florida, USA

⁴⁸Department of Family Medicine and Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, Washington, USA

⁴⁹Academic Consortium for Integrative Medicine and Health, New Buffalo, Michigan, USA

⁵⁰Saint Michael's Hospital Department of Surgery, University of Toronto, Toronto, Ontario, Canada

⁵¹People with Arthritis and Rheumatism, European Alliance for Associations for Rheumatology (EULAR), Kilchberg, Switzerland

⁵²Bone and Joint Research Group, Royal Cornwall Hospitals Trust, Truro, UK

⁵³Department of Rheumatology, Royal North Shore Hospital, University of Sydney, Sydney, New South Wales, Australia

Twitter Andrew M Briggs @AndrewMBriggs, Helen Slater @hels_slater, James J Young @James_J_Young, Saurab Sharma @link_physio and Lyn March @lynmarch1

Acknowledgements We gratefully acknowledge the time and expertise of the participants across the various phases of the work and to Dr Jason Chua for assistance with manuscript preparation. Figure 1 design by Nikki M Group Pty Ltd., Melbourne, Australia (<https://www.nikkimgroup.com.au/>). Participants who consented to being acknowledged are listed below. Argentina: Dr Cecilia Asnal, Ms Mariana Bonetto, Ms Chiara Buzzelli, Dr Ignacio Gandino, Mr Martin Moro, Ms Milagros Rossello, Dr Anastasia Secco. Australia: Associate Professor Ilana Ackerman, Mr Rob Anderson, Professor Robert Blank, Dr Jocelyn Bowden, Ms Prudence Butler, Mr Aidan Cashin, Dr Katie de Luca, Dr James Debenham, Mr Craig Elliott, Professor James Elliott, Ms Caitlin Farmer, Mr James Farmer, Mr Giovanni Ferreira, Professor Manuela Ferreira, Mr Troy Gardiner, Professor Catherine Hill, Professor Rana Hinman, Dr Emma Karran, Dr Richard Kwiatek, Ms Jane Males, Ms Marie March, Mr Rod Mclean, Ms Karime Mescouto, Dr Serg Mezhov, Ms Jennifer Persaud, Mr Radd Peters, Ms Rebecca Phillips, Professor Kevin Pile, Ms Maree Raymer, Mr Rodrigo Rizzo, Dr Luke Robinson, Dr Geoffrey Speldewinde, Dr Hannah Seymour, Professor Cathie Sherrington, Ms Cobie Starcevic, Professor Michele Sterling, Mr Matthew Stewart, Dr Michael Swain, Mr Patrick Swete Kelly, Mr Jay-Shian Tan, Mrs Rosalie Upton, Professor Bill Vicenzino, Dr Andrew Vitiello, Mr Kevin Wernli, Ms Mary Wing. Bangladesh: Professor Rowsan Ara, Mr Mohammad Lutfullah, Professor Mujibur Rahman, Dr Shadab Sunny. Belgium: Professor Liesbet De Baets, Ms Mairead Groarke, Mr Tom Michielsen, Ms Nadine Vanhollebek. Bhutan: Mr Monu Tamang. Brazil: Dr André Barbosa Adriano, Professor Cristina Cabral, Professor Thais Chaves, Dr Eduardo de Melo Carvalho Rocha, Dr Adriana Dell'Aquila, Professor João Garcia, Dr Thaisa Infurna Gomes, Professor Pedro Lima, Ms Marina Magalhães, Professor Guilherme Moreira de Barros, Dr Mauro Salles, Dr Marcela Santa Rosa, Dr Bruno Saragiotto, Mr Marcelo Sternick, Ms Izabel Tavares, Dr Lin Yeng, Professor Fernando Zikan. Canada: Dr Carlo Ammendolia, Dr Jane Barratt, Dr Lauren Beaupre, Dr Mark Bodnar, Dr Douglas Brandvold, Professor Auri Bruno Petrina, Professor Pierre Côté, Dr Diana De Carvalho, Mr Darren Frohlich, Dr Isabelle Gagnon, Ms Annie Grenier, Dr Andrea Guidolin, Mr Stephen Guy, Professor Jeffrey Hebert, Ms Catherine Hofstetter, Dr Greg Kawchuk, Ms Rosemary Kirungyi, Dr Jasmin Ma, Ms Rhona McGlasson, Ms Annette McKinnon, Mr Keith Meldrum, Dr Silvano Mior, Dr Anish Naidu, Dr Paul Nolet, Dr Geoff Outerbridge, Ms Ronda Parkes, Dr Jairus Quesnele, Dr Paolo Sanzo, Dr Patricia Tavares, Dr Natalja Tchajkova, Ms Aileen Tran Mapletoft, Dr Jeff Warren, Dr Jackie Whittaker, Mr Muhammed Zama. Colombia: Mr Luis Henriquez Fuentes, Mr Enrique Sepulveda, Dr Kai Fu, Professor Yueqin Huang, Professor Zhanguo Li, Dr Kiran Shah, Dr Luis Alvarez, Professor Wilson Bautista Molano, Dr Carlo Caballero, Dr Sebastian Herrera, Dr Ryan Murillo, Dr Carlos Toro Gutierrez. Croatia: Dr Lovro Lamot, Dr Sime Mijic. Cyprus: Mr Marios Kouloumas, Ms Souzi Makri. Czech Republic: Dr Tomas Novotny. Denmark:

Professor Jan Hartvigsen, Assistant Professor Morten Hoegh, Professor Alice Kongsted, Professor Claus Nielsen, Ms Anne Skov Østergaard, Ms Mette Toft. Egypt: Dr Hazem Abdelaziz, Professor Ahmad Aly. Estonia: Dr Karin Laas. Finland: Dr Minna Stolt. France: Dr Yargui Audrey, Mr Gaetan Barbier, Professor Francis Berenbaum, Professor Federico Canavese, Dr Karine Cheng, Dr Charlene Chéron, Dr Emmanuelle Cuy, Dr Grace Dubois, Dr Nadège Lemeunier, Dr Mathieu Ménard, Ms Olivia Parker, Dr Audrey Parkinson, Dr Mégane Pasquier, Ms Agathe Wagner. Germany: Dr Gemma Adib, Mr Peter Böhm, Mrs Trisha Davies Knorr, Professor Klaus Günther, Professor Frank Hildebrand, Ms Christine Kuberka Wiese, Professor Andreas Niemeier, Mr Francis Osei, Ms Uta Prehl, Dr Alexandra Rauch, Professor Kati Thieme. Greece: Ms Arezoo Abdi, Ms Katy Antonopoulou, Dr Vasileios Gkolfinopoulos, Dr Christos Topalis. Guatemala: Professor Manuel Padrino. Honduras: Dr Hugo Alonzo. Hong Kong (SAR): Ms Sheila Purves. Hungary: Ms Katalin Forgács Kristóf, Dr Zoltán Grauzer, Dr Zsolt Kálbori, Dr Monika Redly. India: Dr Mohan Bairwa, Ms Shelllette D Almeida, Professor Anil Gupta, Mr Shrikant Iyengar, Professor Ashok Johari, Dr Kalaivanan Kannian, Mr Niraj Karamchandani, Mr Raghava Neelapala, Dr Akshat Pandey, Dr Ruchita Parikh, Dr Dhara Patel, Dr Vivek Ramanandi, Dr Abhinav Singh. Indonesia: Ms Defianti Ariani, Dr Rudy Hidayat, Mr Firmansyah Purwanto. Ireland: Dr Eilish Burke, Mr John Casey, Mrs Wendy Costello, Ms Blanaid Coveney, Dr Anne Dempsey, Ms Petrina Donohue, Ms Angela Doyle, Dr Roger Feely, Dr Diarmaid Fitzgerald, Ms Laura Fletcher, Ms Brenda Foley, Mr Frank Foley, Ms Marion Glasheen, Ms Michelle Heraught, Ms Margaret Kelleher, Dr Gráinne Kelly, Ms Marie Kelly, Ms Orla Madden, Ms Eimear Ni Fhallúin, Dr Marie O'Mir, Ms Helen O'Reilly, Dr Mary O'Keefe, Dr Kieran O'Sullivan, Ms Aisling Reynolds, Ms Stephanie Skeffington, Dr Clodagh Toomey, Ms Grainne Treacy, Ms Mary Walsh. Israel: Ms Carola Oppenheimer Rosenthal, Dr Tali Sahar, Professor Shlomo Wientroub. Italy: Dr Diego Alemanno, Dr Paola Antonaccio, Dr Maria Brugnoli, Dr Luca Canzoneri, Ms Antonella Cardone, Dr Rosario Furnari, Dr Paolo Galimberti, Dr Romano Graziani, Dr Alessandro Guzzo, Professor Francesca Ingegnoli, Dr Gianluca Mascalco, Professor Paolo Marchettini, Dr Mario Marinelli, Dr Cinzia Marzilli, Professor Marco Monticone, Dr Tiziana Nava, Dr Guindani Nicola, Professor Maria Pace, Dr Vincenzo Pota, Dr Bernd Raffaeiner, Dr Vincenzo Sidoti, Dr Madalina Sofica, Ms Silvia Tonolo, Dr Ugo Viora. Japan: Ms Masae Ikeya, Mr Hironobu Kuruma, Dr Kei Takeyachi. Kenya: Mr Shadrack Okumu, Mr Henry Opondo. Latvia: Dr Vladimirs Gromakovskis. Lebanon: Dr Charbel Najem. Malaysia: Ms Nur Abdul Halim, Dr Amir Abdul Latiff, Dr Haidzir Manaf, Dr Jocelyn Ooi, Dr Shivani Rajasegaran, Dr Kandiah Raveendran, Dr La Reina Sangaran, Dr Swee Tang, Professor Meow Thong, Dr Yi Kai Wong. Mexico: Dr Ingris Pelaez Ballestas. Mongolia: Dr Zolzaya Batdavaajav, Ms Batkham Dambadarjaa. Montenegro: Dr Sonja Nejkov. Myanmar: Professor Thaingi Hlaing, Dr Lu Maw Win. Nepal: Ms Nibha Bajracharya, Ms Anushree Balla, Mr Marvin Dewan, Mr Shamed Katila, Ms Bimika Khadgi, Mr Dildip Khanal, Ms Elisa Maharjan, Ms Riju Maharjan, Professor Buddhi Paudyal, Mr Vimal Prajapati, Ms Kanchan Sapkota, Ms Ranjeeta Shijagurumayum Acharya, Mr Bishwas Shrestha, Dr Shaili Thapa. Netherlands: Dr Tjarco Alta, Professor Annelies Boonen, Dr Maarten Heinsius, Dr Nathan Hutting, Dr Alan Jenks, Dr Dagmar Kempink, Ms Patricia Pennings, Professor Johannes Rasker, Dr Mark Scheper, Ms Gitte Tonner, Dr Brenda van der Vossen, Professor Harry von Piekartz, Dr Frank Wagenaar Dr Anemarie de Zoete. New Zealand: Associate Professor Ben Darlow, Dr Jenny Keightley, Mrs Susan Kohut, Associate Professor Peter Larmer, Dr Bronwyn Lennox Thompson, Dr Ramakrishnan Mani, Dr Daniel Ribeiro, Dr David Rice, Professor Debra Waters. Nigeria: Professor Olufemi Adelowo, Mrs Racheal Kareem, Dr Abubakar Yerima. Norway: Mr Hans Engvold, Camilla Fongen, Mr Thor Holmgard, Ms Olea Kvalsvik, Professor Emer Tore Kvien, Dr Lise Lothe, Ms Amy Martinsen, Dr Rikke Moe, Dr Espen Ohren, Dr Tim Raven, Professor May Risberg. Pakistan: Dr Dilshad Al Arabia, Professor Sumaira Farman. Palestine (West Bank and Gaza), Professor Alaaeldin Ahmad. Panama: Dr Antonio Cachafeiro, Dr Enrique Giraldo. Peru: Dr Manuel Ugarte Gil. Philippines: Associate Professor Romel Cabazor, Dr Eunice Co, Professor Monalisa Lim Dungca, Dr Donald Manlapaz, Mr Chris Munoz, Dr Sheila Reyes, Assistant Professor Kathryn Reyes, Dr Maria Gudez-Santos, Assistant Professor Christian Rimando, Ms Zyra Sicut, Dr Lisa Traboco. Poland: Mrs Jolanta Grygielska, Dr Barbara Jasiewicz. Portugal: Professor Jose Da Silva, Dr Ricardo Ferreira, Dr Margarida Freitas, Professor Andréa Marques, Professor Alexandrina Mendes, Dr Anabela Silva. Romania: Professor Mihai Berteanu, Dr Constantin Munteanu. Russian Federation: Professor Olga Lesnyak. Saudi Arabia: Dr Hadeel Bakhsh. Singapore: Associate Professor Madelynn Chan, Mr Anthony Goff, Dr Janet Sosna. Slovenia: Professor Radko Komadina. South Africa: Professor Stanley Brighton, Dr Bridget Bromfield, Mr Grant Bush, Dr Kendrah Da Silva, Ms Dershnee Devan, Dr Ina Diener, Ms Patricia Dunn, Ms Magdalena Ferreira, Mrs Wilna Foot, Professor Pragashnie Govender, Ms Andrea Linser, Dr Victoria Madden, Professor Girish Mody, Dr Farzana Moosajee, Mr Tom Paulsen, Assistant Professor Christiaan Scott, Mrs Veronica Tinley, Ms Maranda van Dam, Mrs Meagan Wright. Spain: Dr Mercedes Boada, Dr Jose Campos, Professor Loreto

Carmona, Dr Gustavo Fabregat, Professor Enrique Gomez Barrera, Dr Pedro Gonzalez Herranz, Dr David Hernandez Herrero, Professor Antonio Herrera, Dr Francisco Luna Cabrera, Dr Victor Mayoral, Dr Juan Ovalles Bonilla, Dr Maria Padilla del Rey, Dr Miren Revuelta, Mr Jon Royo, Dr Francisca Sivera, Dr Javier Vidal Fuentes, Dr Marianna Vitaloni. Sri Lanka: Ms Thusharika Dissanayaka. Sweden: Associate Professor Allan Abbott, Associate Professor Iben Axén, Professor Leif Dahlberg, Professor Ewa Roos, Professor Anne Söderlund. Switzerland: Professor Christine Cedraschi, Mr Guillaume Christe, Dr Alarcos Cieza, Ms Renée de Ruijter, Professor Jean-Yves Reginster, Dr Yuka Sumi, Mr Peter Timmers. Syrian Arab Republic: Dr Layla Kazkaz. Thailand: Assistant Professor Sirirat Charuvani, Assistant Professor Krit Pongpirul. Turkey: Dr Mustafa Agaoglu, Professor Gulseren Akuz, Professor Osman Atik, Dr Ayse Bahsi, Professor Deniz Evcik, Professor Hakan Gunduz, Professor Ozgur Kasapocur, Professor Erkan Kozanoglu, Dr Koncu Sivrioglu, Dr Nuri Ulutas, Dr Vasyil Tsokalo. United Arab Emirates, Dr Manoj Nair. United Kingdom of Great Britain and Northern Ireland: Professor Adewale Adebajo, Mr Richard Beesley, Mr Peter Bobak, Dr Helen Branthwaite, Professor Cyrus Cooper, Professor Matthew Costa, Professor Emeritus Peter Croft, Dr Jerry Draper Rodi, Dr Carol Fawkes, Dr Rob Finch, Dr Guy Gosselein, Mrs Sarah Helmy, Dr Lee Herrington, Professor Michael Hurley, Mr Jonathon Kruger, Mr Stephen Mack Smith, Professor Iain McInnes, Mrs Valerie Moody, Mr Peter Moore, Dr Chris Penlington, Dr Catherine Quinn, Dr Emma Roberts, Ms Claire Small, Dr Toby Smith, Dr Ai Lyn Tan, Ms Jacqueline Thompson, Mr Nick Welch. USA: Ms Christine Anderson, Dr Harvey Aikman, Dr Ivy Alexander, Dr Kris Anderson, Dr Nancy Baker, Dr Cameron Banks, Dr Ann Barry, Dr Anita Bemis-Dougherty, Dr Craig Benton, Ms Jane Borgehammar, Dr William Boissonnault, Dr Harvey Brockman, Dr Melissa Buehler, Mr Daniel Chelette, Ms Kathleen Cody, Dr Kim Coelho, Dr James Corcoran, Dr Zachary Cupler, Dr Jenifer Dice, Dr Jonathan Dolutan, Dr Jan Dommerholt, Dr Matthew Drake, Ms Ann Elderkin, Ms Jennifer Everhart, Dr Mychelle Farmer, Ms Mariann Farrell, Dr Kyle Feldman, Dr Amy Fletcher, Professor Walter Frontera, Dr Angelo Gaffo, Ms Tammy Gersh, Dr Lima Ghulmi, Mr Jeff Giulietti, Professor Joseph Godges, Dr Christine Goertz, Dr Steven Goostree, Dr Erik Groessl, Dr Anthony Hamm, Dr Kim Hecht, Dr Liz Henry, Professor Marc Hochberg, Dr Claire Horn, Dr Evelyn Hsieh, Professor Nitin Jain, Dr Kristin Jerger, Dr Bringa Johnson, Mr Gregory Johnson, Mr Howard Kagan, Dr David Karp, Dr Gary Kearns, Dr Jeff Kittelson, Professor Jonathan Klein, Dr Donnamarie Krause, Dr William Lawson, Dr Craig Liebenson, Dr David Logerstedt, Professor Jonathan Lowery, Ms Tyres Marcy, Professor Lee Marinko, Professor Eric Matteson, Dr Michele Meltzer, Mr Ernest Merritt, Professor Michael Millis, Dr Brittany Minniear, Dr Matthew Morretta, Dr Nathaniel Mosher, Dr Bradley Myers, Lt Col Joseph Norris, Dr Bryan O'Halloran, Dr Kenneth Olson, Dr Colette Peabody, Mr Matt Peale, Professor Janet Poole, Dr Peter Potena, Dr Guillermo Quiceno, Dr Matthew Regulski, Dr Daniel Rendeiro, Dr Robert Rowe, Dr Chris Showalter, Dr Emily Slaven, Dr Marcia Spoto, Dr Christine Stamatos, Dr Eric Stedje-Larsen, Dr Howard Phillips, Dr Brocha Stern, Dr Kimberly Templeton, Assistant Professor Jake Thompson, Dr Robert Trager, Dr Frank Tudini, Mr Philip Tygiel, Mr Stefan van Duursen, Professor Stuart Weinstein, Dr Julie Werner, Dr Adam Wielechowski, Dr Jeff Williams, Dr Richard Wilson, Dr Jeffrey Yaver, Mr Al Zanetell. Uruguay: Dr Miguel Albanese.

Contributors Design of the study—AMB, CHS, HS, SS, DK-G and LMarch. Data collection—AMB, CHS, HS, JEJ, SP, JJJ, SS, DK-G and SMishrra. Data analysis and interpretation—AMB, CHS, HS, JEJ, SP, JJJ, SS, DK-G and LMarch. Preparation of the initial manuscript—AMB and CHS. Revision of the manuscript and approval for publication—AMB, CHS, HS, JEJ, SP, JJJ, SS, DK-G, SMishrra, KEA, NA, JB, NB, FMB, RB, DD, KED, LF, HEF, FG, SH, SAH, BH, AJ, MJ, AAK, JL, SMatsuda, AM, LMwaniki, MCN, MP, FJJR, ERS, HT, JW, DW, ADW and LMarch.

Funding This research was funded by a grant awarded by the Bone and Joint Decade Foundation. Additional funding was provided by Curtin University and The University of Sydney.

Map disclaimer The depiction of boundaries on the map(s) in this article does not imply the expression of any opinion whatsoever on the part of BMJ (or any member of its group) concerning the legal status of any country, territory, jurisdiction or area or of its authorities. The map(s) are provided without any warranty of any kind, either express or implied.

Competing interests AMB reports grants from the Bone and Joint Decade Foundation during the conduct of the study. CHS reports grants from Curtin University during the conduct of the study. HS reports grants from the Bone and Joint Decade Foundation during the conduct of the study; personal fees from AbbVie outside the submitted work. JEJ reports personal fees from Curtin University during the conduct of the study. SP has nothing to disclose. JJJ reports grants from the Danish Foundation for Chiropractic Research and Post-graduate Education, grants from Canadian Memorial Chiropractic College, grants from

Ontario Chiropractic Association, grants from National Chiropractic Mutual Insurance Company Foundation, grants from the University of Southern Denmark Faculty Scholarship outside the submitted work. SS has nothing to disclose. DK-G has nothing to disclose. SMishra reports grants from Curtin University during the conduct of the study. KEA reports personal fees from Amgen, personal fees from UCB, personal fees from FAN, personal fees from Astellas pharma, personal fees from Chugai pharma outside the submitted work. NA has nothing to disclose. JB has nothing to disclose. NB reports personal fees from Amgen, personal fees from Grunenthal, personal fees from Lilly, personal fees from Pfizer, personal fees from Sanofi, personal fees from Global Alliance for Patient Access outside the submitted work. FMB has nothing to disclose. RB reports personal fees from World Federation of Chiropractic outside the submitted work. DD has nothing to disclose. KED has nothing to disclose. LF has nothing to disclose. HEF has nothing to disclose. FG has nothing to disclose. SH has nothing to disclose. SAH has nothing to disclose. BH has nothing to disclose. AJ has nothing to disclose. MJ has nothing to disclose. AAK has nothing to disclose. JL has nothing to disclose. SMatsuda has nothing to disclose. AM reports grants, non-financial support and other from Merck KGaA; grants, non-financial support and other from Kolon TissueGene; grants, non-financial support and other from Merck KGaA; grants from Pfizer; grants from European Commission-Innovative Medicines Initiative (IMI); grants from European Union Structural Funds administered by the Research Council of Lithuania (Lietuvos mokslo taryba); grants from European Union Structural Funds administered by the Research Council of Lithuania (Lietuvos mokslo taryba); grants from European Commission-Framework 7 (FP7-HEALTH); grants from European Commission-Framework 7 (FP7-PEOPLE) Marie Skłodowska-Curie Program; personal fees from Galapagos-Servier; personal fees from Image Analysis Group (IAG); personal fees, non-financial support and other from Artialis SA; personal fees and other from Aché (Aché Laboratórios Farmacêuticos); personal fees and other from Abbvie; personal fees from Guidepoint Global.; personal fees from Alphasights; personal fees from Science Branding Communications; personal fees and non-financial support from Pfizer Consumer Healthcare; non-financial support from GSK Consumer Healthcare; personal fees and other from Flexion Therapeutics; personal fees from Pacira Biosciences; other from Genacol; personal fees, non-financial support and other from Sterifarma; other from Henry Stewart Talks; non-financial support from GlaxoSmithKline (GSK); grants from Versus Arthritis (Arthritis Research UK); personal fees and other from Korean Society for Osteoarthritis and Cartilage Repair; personal fees from American College of Rheumatology; personal fees and other from Spanish Society of Rheumatology; personal fees and other from Heilongjiang Rheumatology Association; personal fees and other from Zhujiang Hospital of Southern Medical University; non-financial support and other from International Cartilage Regeneration and Joint Preservation Society (ICRS); non-financial support and other from Osteoarthritis Research Society International (OARSI); non-financial support from AxDev International; other from Gordian Biotechnology; other from UNITY Biotechnology; personal fees and other from Bioiberica; other from The Dutch Arthritis Society (ReumaNederland); other from Kolon Life Science; personal fees from SANOFI; personal fees from European Commission; other from BRASIT/BRASOS, Brazil; other from GEOS, Brazil; other from European Orthopaedic Research Society (EORS); other from Brazilian Society of Rheumatology (SBR); other from Society for Osteoarthritis Research (SOAR), India; other from MCI Group, Geneva outside the submitted work. LMwaniki has nothing to disclose. MCN has nothing to disclose. MP has nothing to disclose. FJJR has nothing to disclose. ERS reports grants, personal fees and non-financial support from Abbvie; personal fees from Amgen; personal fees from BMS; grants from Glaxo; grants and personal fees from Janssen; personal fees from Lilly; grants and personal fees from Novartis; grants, personal fees and non-financial support from Pfizer; grants and personal fees from Roche; grants, personal fees and non-financial support from UCB outside the submitted work. HT reports having authored two books: *Life Beyond the Carpal Tunnel* (2007) and *Holistic Pain Relief* (2014). JW has nothing to disclose. DW has nothing to disclose. ADW has nothing to disclose. LMarch reports personal fees from Lilly, personal fees from Pfizer, personal fees from Abbvie, grants from Janssen outside the submitted work. LMarch is an executive member of OMERACT which receives funding from 30 different companies.

Patient consent for publication Not required.

Ethics approval Approval to conduct the study was granted by the Human Research Ethics Committee of Curtin University, Australia (HRE2020-0183).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplemental information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been

peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Andrew M Briggs <http://orcid.org/0000-0002-6736-3098>
 Carmen Huckel Schneider <http://orcid.org/0000-0002-7493-3589>
 Helen Slater <http://orcid.org/0000-0002-4868-4988>
 Joanne E Jordan <http://orcid.org/0000-0002-2625-7985>
 Sarika Parambath <http://orcid.org/0000-0002-1464-4638>
 James J Young <http://orcid.org/0000-0003-1210-3106>
 Saurab Sharma <http://orcid.org/0000-0002-9817-5372>
 Deborah Kopansky-Giles <http://orcid.org/0000-0002-4651-3499>
 Swatee Mishra <http://orcid.org/0000-0003-4073-2030>
 Kristina E Akesson <http://orcid.org/0000-0003-3024-2804>
 Nuzhat Ali <http://orcid.org/0000-0003-3807-8535>
 Joletta Belton <http://orcid.org/0000-0001-5174-1691>
 Neil Betteridge <http://orcid.org/0000-0001-8844-1158>
 Fiona M Blyth <http://orcid.org/0000-0001-8824-2546>
 Richard Brown <http://orcid.org/0000-0003-2848-5671>
 Demelash Debere <http://orcid.org/0000-0002-9384-9438>
 Karsten E Dreinhöfer <http://orcid.org/0000-0001-6021-2804>
 Laura Finucane <http://orcid.org/0000-0002-3076-4402>
 Helen E Foster <http://orcid.org/0000-0001-8824-2546>
 Francesca Gimigliano <http://orcid.org/0000-0002-1905-6405>
 Scott Haldeman <http://orcid.org/0000-0002-8688-9562>
 Syed A Haq <http://orcid.org/0000-0003-4154-7283>
 Ben Horgan <http://orcid.org/0000-0001-5800-4539>
 Anil Jain <http://orcid.org/0000-0002-5979-1164>
 Manjul Joshipura <http://orcid.org/0000-0001-5891-8234>
 Asgar A Kalla <http://orcid.org/0000-0001-7970-9730>
 Jakob Lothe <http://orcid.org/0000-0002-1536-7003>
 Shuichi Matsuda <http://orcid.org/0000-0003-0802-1255>
 Ali Mobasheri <http://orcid.org/0000-0001-6261-1286>
 Lillian Mwaniki <http://orcid.org/0000-0003-2653-4978>
 Margareta C Nordin <http://orcid.org/0000-0003-0356-8665>
 Marilyn Pattison <http://orcid.org/0000-0002-7976-506X>
 Felipe J J Reis <http://orcid.org/0000-0002-9471-1174>
 Enrique R Soriano <http://orcid.org/0000-0003-3143-1084>
 Heather Tick <http://orcid.org/0000-0002-8903-2396>
 James Waddell <http://orcid.org/0000-0002-9632-6819>
 Dieter Wiek <http://orcid.org/0000-0002-8778-958X>
 Anthony D Woolf <http://orcid.org/0000-0001-8482-8056>
 Lyn March <http://orcid.org/0000-0003-1736-8111>

REFERENCES

- 1 Cieza A, Causey K, Kamenov K, *et al*. Global estimates of the need for rehabilitation based on the global burden of disease study 2019: a systematic analysis for the global burden of disease study 2019. *Lancet* 2021;396:2006-2017.
- 2 Vos T, Lim SS, Abbafati C, *et al*. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. *The Lancet* 2020;396:1204-22.
- 3 Blyth FM, Briggs AM, Schneider CH, *et al*. The global burden of musculoskeletal pain-where to from here? *Am J Public Health* 2019;109:35-40.
- 4 Organisation for Economic and Co-operation Development. *Health spending: expenditure by disease, age and gender*. Paris: OECD, 2016.
- 5 Dieleman JL, Cao J, Chapin A, *et al*. US health care spending by payer and health condition, 1996-2016. *JAMA* 2020;323:863-84.

- 6 Australian Institute of Health & Welfare. *Disease expenditure in Australia*. Canberra: AIHW, 2019.
- 7 Sharma S, Blyth FM, Mishra SR, *et al*. Health system strengthening is needed to respond to the burden of pain in low- and middle-income countries and to support healthy ageing. *J Glob Health* 2019;9:020317.
- 8 Jackson T, Thomas S, Stabile V, *et al*. A systematic review and meta-analysis of the global burden of chronic pain without clear etiology in low- and middle-income countries: trends in heterogeneous data and a proposal for new assessment methods. *Anesth Analg* 2016;123:739–48.
- 9 GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. *Lancet* 2018;392:1789–858.
- 10 March L, Smith EUR, Hoy DG, *et al*. Burden of disability due to musculoskeletal (MSK) disorders. *Best Pract Res Clin Rheumatol* 2014;28:353–66.
- 11 Foster NE, Anema JR, Cherkin D, *et al*. Prevention and treatment of low back pain: evidence, challenges, and promising directions. *Lancet* 2018;391:2368–83.
- 12 George SZ, Goertz C, Hastings SN, *et al*. Transforming low back pain care delivery in the United States. *Pain* 2020;161:2667–73.
- 13 Briggs AM, Slater H, Hsieh E, *et al*. System strengthening to support value-based care and healthy ageing for people with chronic pain. *Pain* 2019;160:1240–4.
- 14 Mardian AS, Hanson ER, Villarreal L, *et al*. Flipping the pain care model: a sociopsychobiological approach to high-value chronic pain care. *Pain Med* 2020;21:1168–80.
- 15 Blyth FM, Huckel Schneider C. Global burden of pain and global pain policy—creating a purposeful body of evidence. *Pain* 2018;159 Suppl 1:S43–8.
- 16 Briggs AM, Woolf AD, Dreinhöfer K, *et al*. Reducing the global burden of musculoskeletal conditions. *Bull World Health Organ* 2018;96:366–8.
- 17 Hoy D, Geere J-A, Davatchi F, *et al*. A time for action: opportunities for preventing the growing burden and disability from musculoskeletal conditions in low- and middle-income countries. *Best Pract Res Clin Rheumatol* 2014;28:377–93.
- 18 Traeger AC, Buchbinder R, Elshaug AG, *et al*. Care for low back pain: can health systems deliver? *Bull World Health Organ* 2019;97:423–33.
- 19 World Health Organization. *It's time to walk the talk: WHO independent high-level commission on noncommunicable diseases final report*. Geneva: WHO, 2019.
- 20 Briggs AM, Persaud JG, Deverell ML, *et al*. Integrated prevention and management of non-communicable diseases, including musculoskeletal health: a systematic policy analysis among OECD countries. *BMJ Glob Health* 2019;4:e001806.
- 21 NCD Alliance. *The need for a person-centred, inclusive NCD agenda*. Geneva: NCD Alliance, 2020.
- 22 Foster HE, Scott C, Tiderius CJ, *et al*. Improving musculoskeletal health for children and young people - A 'call to action'. *Best Pract Res Clin Rheumatol* 2020;34:101566.
- 23 Williams A, Kamper SJ, Wiggers JH, *et al*. Musculoskeletal conditions may increase the risk of chronic disease: a systematic review and meta-analysis of cohort studies. *BMC Med* 2018;16:167.
- 24 Simões D, Araújo FA, Severo M, *et al*. Patterns and consequences of multimorbidity in the general population: there is no chronic disease management without rheumatic disease management. *Arthritis Care Res* 2017;69:12–20.
- 25 Schofield DJ, Shrestha RN, Cunich M, *et al*. Lost productive life years caused by chronic conditions in Australians aged 45–64 years, 2010–2030. *Med J Aust* 2015;203:260.
- 26 GBD 2019 Viewpoint Collaborators. Five insights from the global burden of disease study 2019. *Lancet* 2020;396:1135–59.
- 27 Lidgren L. Looking back at the start of the bone and joint decade what have we learnt? *Best Pract Res Clin Rheumatol* 2012;26:169–71.
- 28 Buchbinder R, van Tulder M, Öberg B, *et al*. Low back pain: a call for action. *Lancet* 2018;391:2384–8.
- 29 Cohen SP, Vase L, Hooten WM. Chronic pain: an update on burden, best practices, and new advances. *Lancet* 2021;397:2082–97.
- 30 Hunter DJ, March L, Chew M. Osteoarthritis in 2020 and beyond: a Lancet Commission. *Lancet* 2020;396:1711–2.
- 31 Jamison DT, Summers LH, Alleyne G, *et al*. Global health 2035: a world converging within a generation. *Lancet* 2013;382:1898–955.
- 32 World Health Organization. *Framework on integrated, people-centred health services*. Geneva: World Health Organization, 2016.
- 33 World Health Organization Regional Office for Europe. *Action plan for the prevention and control of noncommunicable diseases in the WHO European region*. Copenhagen: WHO Regional Office for Europe, 2016.
- 34 World Health Organization. *Integrated care for older people (ICOPE): guidance for person-centred assessment and pathways in primary care*. Geneva: WHO, 2019.
- 35 Rauch A, Negrini S, Cieza A. Toward strengthening rehabilitation in health systems: methods used to develop a who package of rehabilitation interventions. *Arch Phys Med Rehabil* 2019;100:2205–11.
- 36 Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. *Int J Qual Health Care* 2007;19:349–57.
- 37 Staniszewska S, Brett J, Simeria I. GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research.. *BMJ* 2017;358:j3453.
- 38 Briggs AM, Jordan JE, Kopansky-Giles D. The need for adaptable global guidance in health systems strengthening for musculoskeletal health. A qualitative study of international key informants. *Glob Health Res Policy* 2021.
- 39 World Health Organisation. *Global action plan for the prevention and control of noncommunicable diseases 2013–2020*. Geneva: WHO, 2013.
- 40 Briggs AM, Araujo de Carvalho I, Carvalho Adel. Actions required to implement integrated care for older people in the community using the world Health organization's ICOPE approach: a global Delphi consensus study. *PLoS One* 2018;13:e0205533.
- 41 Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *Int J Soc Res Methodol* 2005;8:19–32.
- 42 Anderson S, Allen P, Peckham S, *et al*. Asking the right questions: scoping studies in the commissioning of research on the organisation and delivery of health services. *Health Res Policy Syst* 2008;6:7.
- 43 Briggs AM, Chan M, Slater H. Models of care for musculoskeletal health: moving towards meaningful implementation and evaluation across conditions and care settings. *Best Pract Res Clin Rheumatol* 2016;30:359–74.
- 44 Hsieh H-F, Shannon SE. Three approaches to qualitative content analysis. *Qual Health Res* 2005;15:1277–88.
- 45 Fitch K, Bernstein SJ, Aguilar MA. *The RAND/UCLA Appropriateness Method User's Manual*. Santa Monica, CA: RAND, 2001.
- 46 Briggs AM, Houlding E, Hinman RS, *et al*. Health professionals and students encounter multi-level barriers to implementing high-value osteoarthritis care: a multi-national study. *Osteoarthritis Cartilage* 2019;27:788–804.
- 47 Cunningham M, Wells M. Qualitative analysis of 6961 free-text comments from the first National cancer patient experience survey in Scotland. *BMJ Open* 2017;7:e015726.
- 48 Briggs AM, Jordan JE, Jennings M, *et al*. Supporting the evaluation and implementation of musculoskeletal models of care: a globally informed framework for judging readiness and success. *Arthritis Care Res* 2017;69:567–77.
- 49 Arthritis Alliance of Canada. *Joint action on Arthritis- a framework to improve arthritis prevention and care in Canada*. Ottawa, Canada, 2012.
- 50 Australian Government, Department of Health. *Australian National strategic action plan for pain management*. Canberra, Australia, 2019.
- 51 Australian Government, Department of Health. *National strategic action plan on arthritis*. Canberra, Australia, 2019.
- 52 Australian Government, Department of Health. *Australian National strategic action plan on Osteoporosis*. Canberra, Australia, 2019.
- 53 Belgium Federal Public Agency for Public Health and Safety. *Aanpak van chronische pijn in België: Verleden, heden en toekomst*. Brussels, Belgium, 2011.
- 54 Briggs AM, Jordan JE, Jennings M. *A framework to evaluate musculoskeletal models of care*. Cornwall, UK: Global Alliance for Musculoskeletal Health of the Bone and Joint Decade, 2016.
- 55 City of Madrid. *Estrategiade Atenciónal Dolor 2017–2020*. Madrid, Spain, 2017.
- 56 Public Health England. *Musculoskeletal health: a 5 year strategic framework for prevention across the lifecourse*. London, England, 2019.
- 57 Directorate General Health Portugal. *Plano Estrategico Nacional de Prevencao E Controlo dA DOR (PENPCDor)*. Lisbon, Portugal, 2017.
- 58 Directorate General of Health Programming of Italy. *Piano Nazionale della Cronicità*. Rome, Italy, 2016.
- 59 European Agency for Safety and Health at Work. *Norway: together for a good working environment*. Oslo, Norway, 2007.

- 60 European Commission. *Occupational health and safety risks in the healthcare sector-Guide to prevention and good practice*. Luxembourg City, Luxembourg, 2010.
- 61 European League Against Rheumatism, European Federation of National Associations of Orthopaedics and Traumatology. *European action towards better musculoskeletal health*. Lund, Sweden, 2017.
- 62 Expert Group on Management of Chronic Pain and Cancer Pain. *Kroonisen kivun ja syöpäkivun hoidon kansallinen toimintasuunnitelma vuosille 2017–2020*. Helsinki, Finland, 2017.
- 63 Government of Chile. *Estrategia Nacional de Salud para El cumplimiento de Los Objetivos Sanitarios de la Década 2011-2020*. Santiago, Chile, 2011.
- 64 Government of Hungary. *Egészséges Magyarország 2014-2020*. Budapest, Hungary, 2014.
- 65 Institute of Medicine. *Committee on advancing pain research care and education. relieving pain in America: a blueprint for transforming prevention, care, education, and research*. Washington, DC, USA, 2011.
- 66 Institute of Musculoskeletal Health and Arthritis. *Strategic plan 2014-2018: enhancing musculoskeletal, skin and oral health*. Ottawa, Canada, 2014.
- 67 Interagency Pain Research Coordinating Committee. *National pain strategy: a comprehensive population health-level strategy for pain*. Washington, DC, USA, 2011.
- 68 Korean Ministry of Health and Welfare. 제3차 국민건강증진종합계획 (2011~2020). Seoul, South Korea, 2011.
- 69 Ministry of Health and Solidarity France. *Plan d'amélioration de la prise en charge de la douleur, 2006 - 2010*. Paris, France, 2006.
- 70 Ministry of Labor France. *Plan santé au travail, 2016-2020*. Paris, France, 2016.
- 71 Ministry of Labor of Columbia. *Plan Nacional de Seguridad y Salud en el Trabajo 2013 - 2021*. Bogota, Columbia, 2014.
- 72 National Health Board of Denmark. *Anbefalinger for tværsektorielle forløb for mennesker med kroniske lænderygsmerter*. Copenhagen, Denmark, 2017.
- 73 National Health Committee of New Zealand. *Low back pain: a pathway to prioritisation*. Wellington, New Zealand, 2014.
- 74 National Health Committee of New Zealand. *Low back pain (LBP) tier 2 assessment*. Wellington, New Zealand, 2015.
- 75 National Institute for Occupational Safety and Health. *Musculoskeletal health program*. Washington, DC, USA, 2019.
- 76 New Zealand Ministry of Health. *The mobility action program*. Wellington, New Zealand, 2015.
- 77 Norwegian Ministry of Health and Care Services. *Folkehelsemeldinga 2018-2019: Gode liv i eit trygt samfunn Oslo, Norway*, 2018.
- 78 Osteoarthritis Action Alliance, Centers for Disease Control and Prevention. *A national public health agenda for osteoarthritis: 2020 update*. Washington, DC, USA, 2020.
- 79 Public Health Agency of Turkey. *Türkiye KAS ve İskelet Sistemi Hastalıkları Önleme ve Kontrol program (2015-2020)*. Ankara, Turkey, 2015.
- 80 Public Health England, NHS England. *Musculoskeletal core capabilities framework for first point of contact practitioners*. London, England, 2018.
- 81 Royal College of Physicians of Ireland, Health Service Executive. *The model of care for rheumatology in Ireland*. Dublin, Ireland, 2015.
- 82 Scottish Government. *Future provision of specialist residential chronic pain management services in Scotland*. Edinburgh, Scotland, 2014.
- 83 Swiss Confederation, Federal Office of Public Health and Swiss Conference of Cantonal Health Directors. *Nationales Strategie Prävention nichtübertragbarer Krankheiten (NCD-Strategie) 2017 – 2024*. Bern, Switzerland, 2016.
- 84 Swiss Rheumatism League. *Nationale Strategie Muskuloskeletale Erkrankungen (2017-2022)*. Bern, Switzerland, 2017.
- 85 Canadian Pain Taskforce. *Chronic pain in Canada: laying a foundation for action*. Ottawa, Canada, 2019.
- 86 Government of the United Kingdom. *Developing partnerships and a whole-system approach for the prevention of musculoskeletal conditions in England*. London, England, 2018.
- 87 Scottish Government. *Allied health professional (AHP) musculoskeletal pathway framework (national minimum standard)*. Edinburgh, Scotland, 2014.
- 88 US Department of Labor. *Improving Pain Management and Support for Workers with Musculoskeletal Disorders: Policies to Prevent Work Disability and Job Loss*. Washington, DC, USA, 2017.
- 89 Welsh Government. *Living with persistent pain in Wales*. Cardiff, Wales, 2019.
- 90 Speerin R, Needs C, Chua J, et al. Implementing models of care for musculoskeletal conditions in health systems to support value-based care. *Best Pract Res Clin Rheumatol* 2020;34:101548.
- 91 World Health Organization. *Decade of healthy ageing 2020–2030*. Geneva: WHO, 2020.
- 92 World Health Organization. *Everybody's business: Strengthening health systems to improve health outcomes. WHO's framework for action*. Geneva: WHO, 2007.
- 93 Menear M, Blanchette M-A, Demers-Payette O, et al. A framework for value-creating learning health systems. *Health Res Policy Syst* 2019;17:79.
- 94 World Health Organisation. *Rehabilitation in health systems*. Geneva: WHO, 2017.
- 95 World Health Organization. *Global strategy on human resources for health: workforce 2030*. Geneva: WHO, 2016.
- 96 World Health Organisation. *Global strategy and action plan on ageing and health*. Geneva: WHO, 2016.
- 97 Ferreira GE, Buchbinder R, Zadro JR, et al. Are musculoskeletal conditions neglected in national health surveys? *Rheumatology* 2021. doi:10.1093/rheumatology/keab025. [Epub ahead of print: 25 Jan 2021].
- 98 Bowden JL, Hunter DJ, Feng Y. How can neighborhood environments facilitate management of osteoarthritis: a scoping review. *Semin Arthritis Rheum* 2021;51:253–65.
- 99 Pathak A, Sharma S, Jensen MP. The utility and validity of pain intensity rating scales for use in developing countries. *Pain Rep* 2018;3:e672.